



**European  
Society of  
Hypertension**

# ESH Council Meeting Agenda

BOLOGNA, NOVEMBER 3, 2018

# 1. PRESIDENT'S WELCOME

*(K. Tsioufis)*

*Apologies: M. Azizi, M. Bochud, M. Burnier, A. Manolis, B. Williams,*

## 2. MINUTES OF BARCELONA SCIENTIFIC COUNCIL MEETING - JUNE 8, 2018

*(R. Kreutz, R. Lynch)*

## Minutes of the Meeting of the ESH Scientific Council

Barcelona, June 8, 2018  
8:15 - 13:00 hrs

### Present

K. Tsioufis, President  
E. Lurbe, Vice President  
R. Kreutz, Secretary  
M. Bochud, Treasurer  
E. Agabiti Rosei, Immediate Past President

### ESH Council members

M. Azizi  
A. Januszewicz  
T. Kahan  
J. Polonia  
P. van de Borne  
B. Williams

### Ex-officio members

C. Borghi  
D. Lovic

### Apologies

P. van de Borne

### Executive officers

G. Mancina  
G. Parati  
D. Clement  
A. Coca  
A. Manolis

### Further Participants

M. Burnier (from 11:00 hrs)  
M. Massaro - AIM  
R. Lynch

### 1. PRESIDENT'S WELCOME

The meeting was opened by the ESH President K. Tsioufis who welcomed Council members to the Annual Meeting. He suggested covering only the most important issues in this meeting and to refer all other issues to the Council Meeting in November.

### 2. MINUTES OF THE BARCELONA SCIENTIFIC COUNCIL MEETING, FEBRUARY, 2018

The minutes of the Council Meeting held in Barcelona, February, 2018 were unanimously accepted by the Council.

### 3. TREASURER'S REPORT

#### a. ESH

M. Bochud presented the audited financial report at 31.12.2017. The total assets of the ESH amount to 2'068'681.83 Swiss francs. The net result for the year amounts to 490'477.01 Swiss francs. Total cash amounts to 1'261'221.58 Swiss francs. She pointed out that after consulting with M. Burnier, the Auditors admonished that the FESH reserves are too low compared to the amount of €700.000 when the FESH was founded. They suggested that €300.000 be transferred by ESH to FESH. This suggestion was unanimously accepted by the Council. M. Burnier reported the Auditors.

European Society of Hypertension, Zsg			
Balance sheet as at 31 December (in Swiss francs)			
Assets	Notes	2017	2016
<b>Current assets</b>			
Cash and cash equivalents	3	1'261'221.58	797'600.25
Short-term investments with a quoted market price		539'211.35	487'854.00
Securities (cost price)		702'914.76	702'914.76
Valuation on securities		-164'703.41	-206'060.78
Trade receivables		149'055.10	158'215.50
due from third parties		149'055.10	158'215.50
Other current receivables		2'178.10	7'368.65
due from third parties		2'178.10	7'368.65
Accrued income and prepaid expenses		117'015.10	114'138.12
<b>Total assets</b>		<b>2'068'681.83</b>	<b>1'575'963.92</b>
<b>Liabilities</b>			
<b>Short-term liabilities</b>			
Accrued expenses and deferred income		29'273.00	26'132.10
<b>Total short-term liabilities</b>		<b>29'273.00</b>	<b>26'132.10</b>
<b>Equity</b>			
Equity		530'044.89	530'044.89
Society capital		1'012'988.83	834'987.81
Retained earnings		490'477.01	78'029.02
<b>Total Equity</b>		<b>2'039'498.83</b>	<b>1'549'031.82</b>
<b>Total liabilities</b>		<b>2'068'681.83</b>	<b>1'575'963.92</b>

European Society of Hypertension, Zug			
Profit and loss statement for the financial year ended 31 December (in Swiss francs)			
	Notes	2017	2016
Net proceeds from sales of goods and services	1532'169.89	1'377'919.76	
Subscriptions	362.16	754.16	
Various meeting income	19'727.80	82'262.40	
Income Meeting Milan	1'296'685.01	-	
Income Meeting Paris	-	1'329'144.29	
Royalties received	1'179'658.83	1'123'886.96	
Purchases and manufacturing costs of products and services sold	-1'122'751.96	-1'162'478.65	
Donations	-	-11'644.00	
Various meeting costs	-49'923.28	-77'450.45	
Expenses Meeting Milan	-154'502.18	-	
Expenses Meeting Paris	-	-124'734.25	
Awards granted	-1'127.30	-	
Joint ESH/ISH Guidelines for the management of Arterial Hypertension	-	-32'640.00	
Other operating expenses	-4'769.62	-109'101.72	
Administrative costs	8'041.40	-7'846.40	
Legal and professional fees	-32'226.25	-29'157.73	
Other activities	8'808.80	13'197.79	
Bank charges	-354.87	-230.82	
Website expenses	-899.00	-898.00	
Financial income	139'650.90	51.10	
Dividend and interest on securities	247.95	262.85	
Cash interest	-	56.45	
Gain on securities	4'357.35	-	
Gain on currency exchange	89'948.60	-	
Financial expenses	-	-17'217.51	
Loss on securities	-	-8'388.08	
Loss on currency exchange	-	-8'277.48	
Extraordinary non-recurring or prior-period income	2'716.60	-	
Result before taxes	480'477.61	815'522.87	
Direct taxes	8'000.00	-13'603.96	
Net result for the year	480'477.61	782'918.91	

**b. ESH FOUNDATION**

M. Burnier presented the financial report of the Foundation of ESH at 31.12.2017. The total assets were 290'285.41 Swiss francs. The net result for the year amount to 5'736.76 Swiss francs. Total cash amounts to 240'546.21 Swiss francs.

No funds were transferred by ESH to FESH in 2016-2017. He suggested to make a transfer. K. Tsioufis confirmed the transfer of 300,000 Euro to the FESH. K. Tsioufis confirmed that this transfer was unanimously accepted by the Council.

FOUNDATION (FESH)			
Balance sheet as at 31 December (in Swiss francs)			
	Notes	2017	2016
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents	240'546.21	351'964.89	
Short-term investments with a quoted market price	48'619.40	476'800.00	
Securities (over priced)	8'324.00	8'324.00	
Valuation on securities	-17'846.00	-18'217.99	
Trade receivables	9'548.00	-	
due from third parties	9'248.00	-	
<b>Total current assets</b>	<b>290'285.61</b>	<b>393'580.94</b>	
<b>Total assets</b>	<b>290'285.61</b>	<b>393'580.94</b>	
<b>Liabilities</b>			
<b>Short-term liabilities</b>			
Trade payables	6'000	9'227	
due to third parties	6'000	9'227	
Accrued expenses and deferred income	18'000.00	40'931.47	
<b>Total short-term liabilities</b>	<b>22'000.00</b>	<b>49'558.77</b>	
<b>Equity</b>			
Foundation capital	700'000.00	700'000.00	
Retained earnings	-359'717.83	-227'889.55	
Net result for the year	-297'746.76	-120'696.28	
<b>Total Equity</b>	<b>290'285.61</b>	<b>341'613.17</b>	
<b>Total liabilities</b>	<b>290'285.61</b>	<b>393'580.94</b>	

FOUNDATION (FESH)			
Profit and loss statement for the financial year ended 31 December (in Swiss francs)			
	Notes	2017	2016
Net proceeds from sales of goods and services	14'963.95	16'214.61	
Subscriptions of Organizations	6'489.60	2'197.90	
Contributions to Summer School	-	5'440.71	
Contributions to Educational Meeting	5'850.75	8'576.00	
General meeting income	2'223.60	-	
Purchases and manufacturing costs of products and services sold	-14'265.63	-125'826.81	
Foundation activities: Summer School	-62'504.48	-108'022.51	
Foundation activities: Educational Meeting	-11'850.95	-17'803.30	
Other operating expenses	-23'346.43	-26'539.76	
Administrative costs	-21'023.75	-23'554.00	
Legal and professional fees	-3'888.00	-2'547.85	
Bank charges	-434.68	-437.91	
Financial income	10'826.80	8'962.88	
Dividend and interest on securities	901.65	953.65	
Gain on securities	-	294.35	
Gain on currency exchange	9'524.15	6'914.68	
Financial expenses	-	-1'524.65	
Loss on securities	-1'524.65	-	
Net result for the year	-79'736.76	-128'888.28	

**4. ESH 2018**

The annual meeting is the most important activity of the Society and K. Tsioufis thanked A. Coca and M. Massaro for the excellent organization of the 2018 ESH meeting in Barcelona.

**a. Report on 2018 ESH Meeting, Barcelona**

M. Massaro summarized the status of the 2018 Annual Meeting in Barcelona. There is a higher income with less registered participants in 2018 than in 2017. The number of free registrations in 2018 was reduced. Final numbers will be provided at the Council meeting in November.

28 <sup>th</sup> EUROPEAN MEETING ON HYPERTENSION AND CARDIOVASCULAR PROTECTION		BUDGET	
PROVISIONAL			
Please note that the minimum values guaranteed to the ESH and to the LOC are already calculated in this prospect. (€ 100,000.00 each)			
Sponsorship incomes – confirmed (less € 260,000 – ESH 2017)	€ 823.375,00		
Registrations - updated to 07-06-2018	€ 1.106.633,00		
Expenditures - preliminary	€ 1.897.925,00		
<b>PRELIMINARY RESULT</b>	<b>€ 32.083,00</b>		

A total of 1145 Abstracts were received. 1015 Abstracts and 121 Late-breaker abstracts were accepted. 190 were not included in the Abstract Book due to lack of registration fee payment and 24 were withdrawn by the authors. The countries that submitted the most abstracts were Italy, Russia and Spain. The e-Supplement 1 – ESH Abstract Book was

published in the June edition of the Journal of Hypertension. The Abstract Book is available on the Journal of Hypertension website, the ESH website and the ESH congress website.

M. Massaro provided costs for the publication of 922 meeting Abstracts. The cost for the online publication was €11.828,09. R. Kreutz reported that the proposal from the last Council meeting to explore the possibility to publish the abstracts in Blood Pressure was evaluated. However, as agreed the proposal by this Journal was rejected as the costs are in fact even somewhat higher compared to the Journal of Hypertension.

282 Faculty members were invited. The 2018 ESH meeting hosted 1 Sponsored Lecture (Menarini Group), 2 Satellite Symposia (Servier, Merck KGaA), 1 Hands-on Session (Somnomedics), 10 Minisymposia (CVRx, Ferrer (2), Medtronic, Menarini Group (2), Omron Healthcare Europe, ReCOR Medical, Servier (2)).

The 2018 ESH meeting hosted 26 Exhibitors in a total surface of approx. 470 SQM. The total number of registered participants in 2018 is 2565.

A brief brainstorming followed on how to reduce costs of the Annual Meeting and how to attract participants and sponsors. Ideas discussed:

- reduce the length of the congress
- begin on Thursday and finish on Sunday
- work closely with the National Societies encouraging them to bring more physicians
- involvement of local society in meeting organization to bring financial support from local sponsors
- invite local society to hold their meeting (½ day) at the ESH Annual Meeting
- provide special registration fees for Latin American countries
- take into consideration Ramadan when programming the annual meeting

**b. Awards**

The awards committee selected from nominations received the below awards. Prof. Beaufils unable to participate; M. Azizi will receive the Paul Milliez Award on his behalf.

4. ESH 2018

<p>Members of the Award Committee</p> <p>K. Tsioufis E. Agabiti Rosei E. Lurbe A. Coca R. Kreutz</p> <p>February 2018: announcement on website and per Email circulation among ESH members; deadline March 30, 2018</p> <p>Selection of winners during TC with all committee members participating on May 2, 2018</p>	<p style="text-align: center;"><b>ESH AWARDS 2018</b></p> <ul style="list-style-type: none"> <li>• ALBERTO ZANCHETTI LIFE ACHIEVEMENT AWARD Prof. Sverre E. Kjeldsen</li> <li>• ESH HONORARY MEMBER Prof. Patricio Lopez-Jaramillo</li> <li>• BJÖRN FOLKOW AWARD &amp; LECTURE Prof. Dominik N. Müller</li> <li>• TALAL ZEIN AWARD Prof. Costas Thomopoulos</li> </ul>
---	--

**c. Presentation of 2018 ESC/ESH Guidelines on the management of Arterial Hypertension**

Despite the many difficulties the 2018 European Guidelines will be presented at the ESH 2018 Annual Meeting.

K. Tsioufis thanked the two chairs G. Mancia and B. Williams for their excellent contribution and efforts in preparing the Guideline publication.

K. Tsioufis informed the Council members that the Amendment to the agreement with ESC granted ESH the right to broadcast the presentation of the Guidelines in live streaming.

The full text of the new joint Guidelines will be published on August 25 in the European Heart Journal and the Journal of Hypertension, in parallel with a corresponding presentation during the ESC congress in Munich. The Guidelines will be published on the ESH website on the same day.



**d. ESH Collaboration with National Societies**

The active involvement in ESH activities is essential to strengthen relationships between ESH and the National Societies.

**e. Individual appointments with National Society Presidents**




A series of individual meetings, 25 in total, with the Presidents of the National Societies have been organized each morning over the three days of the Annual Meeting. A **Summary Sheet** was sent to all the National Societies asking them to provide an overview of their society.

D. Lovic will finish his term in 2019 as ESH representative of the National Societies. The new representative will be elected by the presidents of the National societies before the June meeting 2019.

**5. ESH BY-LAWS UPDATE 2018**

R. Kreutz summarized the procedure followed to update the current ESH By-laws dated 2002. The text, both in English and in German, was approved by the Swiss law firm Ornitag. The updated By-laws include important changes related to addressing the role of FESH, simplified criteria for membership application, corporate membership, Ex-officio non-voting members and the Awards committee. No objections were raised by the Council.

The By-laws will be presented during the ESH General Assembly for approval.



**6. FUTURE MEETINGS**

**a. 2019 ESH Meeting, Milan**

The meeting will be held 21-24 June, 2019. The layout will be similar to the 2017 layout.

**b. 2020 ESH/ISH Meeting, Glasgow**

The agreement between ESH/ISH will be signed during the meeting on June 11. The City of Glasgow and Tourist Bureau have committed to a financial contribution which is contingent to the number of participants.



**c. 2021 ESH Meeting, Milan**

Nothing to report.

**d. 2022 BID Meeting Candidature**

The presentation of the Bid proposals will take place on Saturday, June 9. The Selection Committee will review the presentations and the announcement of the winner will be made during the General Assembly on Sunday, June 10.

**7. ESH MEMBERSHIP STATUS**

R. Kreutz provided a brief overview of the membership statistics on the payment status.

## 7. ESH MEMBERSHIP STATUS

(R. Kreutz, R. Lynch)

• ESH Members (31/01/18) - **1,742**

• ESH Members (31/05/18) - **1,818**

	2017	2018 (31/05/18)
ESH MEMBERSHIP RENEWALS	322	606

• ESH membership applications (01/06/17-31/01/18) – **120** from **48** countries worldwide

• ESH membership applications (01/02/18-31/05/18) – **181** from **58** countries worldwide

**8. ESH AND JOURNAL OF HYPERTENSION**

K. Tsioufis thanked G. Mancia for guaranteeing the smooth conduction of the Journal of Hypertension during Alberto Zanchetti's recovery in hospital and after his death. He also announced that G. Mancia has been nominated by ESH for the Editor in Chief of the Journal of Hypertension for the next three years. G. Mancia added that in this interim period it is necessary to define new editorial management criteria. More involvement by ISH is needed and Associate Editors should be made more independent. A meeting of the Board of Management of JH to clarify the nomination/election of the new editor is scheduled on 9th June 2018

**9. ESH YOUNG INVESTIGATOR'S FORUM**

J. Polonia apologized for the delay in implementing the forum. Contacts with young physicians has brought to light that hypertension is not very interesting to them. Implement ways to attract young physicians and create interest in hypertension by inviting them to the Summer Schools, develop online program featuring hypertension and multiple diseases (Working Group topics), provide diploma. The core procedure will be presented during the Council meeting in November.

**10. RULES AND ENDORSEMENT OF THE PRE – AND POST – SATELLITE SYMPOSIA AND INDUSTRY SUPPORTED SYMPOSIA**

T. Kahan gave a brief overview of the diversities and rules in different countries and industries regarding the endorsement of pre- and post- satellite symposia and industry supported symposia. Guidelines regulating the above endorsements will be created and will be presented at the next Council meeting.

**11. ESH RESEARCH PROJECTS****a. BP Controls in European Countries**

B. Jelakovic advised that the protocol and Informed Consent have been sent out to the participating Excellence Centres. Some Centres have requested the translation of the protocol and Informed Consent, National Societies will be asked to collaborate with the translations. Omron will deliver the devices to B. Jelakovic who will arrange shipment to the Excellence Centres. The Study will begin in September.

**b. ESH App Pilot Study**

A grant has been received from Pfizer to fund this study which will be carried out in 6 European countries.

**c. Atrial Fibrillation**

The enrolment of approximately 1000 patients has closed.

**12. ESH POSITION PAPERS**

C. Borghi reported he is still waiting for contributions from authors of the Position Paper Nutraceutical for the management of high blood. The final draft will be ready for presentation during the Council Meeting in Bologna.

**13. ESH NEWSLETTERS FOR 2018-2019**

Three new newsletters were published in 2018.

**14. ESH ENDORSEMENT (Books, Meetings)**

The 1<sup>st</sup> North Eastern Postgraduate Course "Arterial Stiffness and Vascular Aging", 15-16<sup>th</sup> November, 2018, Vilnius, Lithuania was endorsed.

**15. ESH and CHL/INDIAN COLLABORATION**

E. Agabiti reported that collaboration with the India began last year. C.Tsioufis reported that Webinars will be broadcast during the Annual Meeting in Barcelona.

E. Agabiti reported the first Spring School in Beijing, China was a success and will be repeated next year. 120 doctors participated in the Spring School. A joint session with the CHL will be held during the Annual Meeting in Barcelona.



**16. ESH SUMMER SCHOOL IN SWITZERLAND**

M. Burnier informed the Council that the final program for the Summer School is ready with the participation of around 77 young physicians.

Many applications have been received from non-European countries eg. Iraq, Yemen, Egypt, Korea, Argentina. A discussion followed on whether only European physicians should be allowed to attend. In the light of the relationships with Latin America and other non-European countries, G. Mancia suggested flexibility to accept non-European participants.

The Society should be more involved in the Summer Schools and the programme should be sent to the President for approval.

The Summer School budget is €100.000. It was suggested to involve local speakers to keep costs low.

D. Lovic accepted to host the 2020 Summer School in Serbia.

**17. DATES FOR FUTURE COUNCIL MEETINGS**

- a. Bologna (Italy), 3 November, 2019
- b. Milan (Italy), 2019 (TBC)
- c. Milan (Italy), 21 June, 2019

**18. ANY OTHER ISSUES**

- a. B. Jelakovic reported four applications from Austria, Belarus, Brazil, Germany for had been received for Excellence Centre status. The applications were approved.
- b. M. Burnier reported the Auditors admonished the FESH's reserves are too low compared to the capitol of €700.000 when the FESH was founded. €300.000 will be transferred by ESH to FESH.
- c. The live streaming of the Guidelines during the Annual Meeting presentation was confirmed.

**19. CLOSURE OF THE MEETING**

K. Tsioufis thanked all the ESH Scientific Council members for attending and wished them a successful ESH meeting.



**Konstantinos Tsioufis**  
ESH President



**Reinhold Kreutz**  
ESH Secretary

# 3. TREASURER'S REPORT

*(M. Burnier)*

# 3. TREASURER'S REPORT *(M. Burnier)*

## European Society of Hypertension, 6300 Zug

Income and Expenditures as per 30.09.2018 (provisional, not audited)

	30.09.2018 (CHF)	31.12.2017 (CHF)
<b>Net assets at beginning of period</b>	<b>2'039'409</b>	<b>1'548'932</b>
<b>INCOME</b>		
<b>Meeting income</b>		
Meeting Milan	0 0.0%	1'266'488 73.9%
General Meeting income	10'718 9.7%	197'338 11.5%
<b>Total Meeting income</b>	<b>10'718 9.7%</b>	<b>1'463'826 73.9%</b>
<b>Subscriptions</b>		
Subscriptions	237 0.2%	382 0.0%
Subscriptions/donations Organisations	97'024 87.7%	0 0.0%
<b>Total Subscriptions</b>	<b>97'261 87.9%</b>	<b>382 0.0%</b>
<b>Other income</b>		
Dividend/Interest securities	255 0.2%	248 0.0%
Gain/Loss on securities	0 0.0%	41'357 2.4%
Exchange difference	0 0.0%	86'949 5.1%
Royalties received	0 0.0%	117'951 6.9%
Extraordinary income	2'439 2.2%	2'277 0.1%
<b>Total Other income</b>	<b>2'695 2.4%</b>	<b>248'782 14.5%</b>
<b>Total INCOME</b>	<b>110'674 100.0%</b>	<b>1'712'990 100.0%</b>

# 3. TREASURER'S REPORT *(M. Burnier)*

## European Society of Hypertension, 6300 Zug

Income and Expenditures as per 30.09.2018 (provisional, not audited)

	30.09.2018 (CHF)	31.12.2017 (CHF)
<b>Net assets at beginning of period</b>	<b>2'039'409</b>	<b>1'548'932</b>
<b>INCOME</b>		
<b>Meeting income</b>		
Meeting Milan	0 0.0%	1'266'488 73.9%
General Meeting income	10'718 9.7%	197'338 11.5%
<b>Total Meeting income</b>	<b>10'718 9.7%</b>	<b>1'463'826 73.9%</b>
<b>Subscriptions</b>		
Subscriptions	237 0.2%	382 0.0%
Subscriptions/donations Organisations	97'024 87.7%	0 0.0%
<b>Total Subscriptions</b>	<b>97'261 87.9%</b>	<b>382 0.0%</b>
<b>Other income</b>		
Dividend/Interest securities	255 0.2%	248 0.0%
Gain/Loss on securities	0 0.0%	41'357 2.4%
Exchange difference	0 0.0%	86'949 5.1%
Royalties received	0 0.0%	117'951 6.9%
Extraordinary income	2'439 2.2%	2'277 0.1%
<b>Total Other income</b>	<b>2'695 2.4%</b>	<b>248'782 14.5%</b>
<b>Total INCOME</b>	<b>110'674 100.0%</b>	<b>1'712'990 100.0%</b>

## EXPENDITURE

Allowance to the FESH	360'450 325.7%	0 0.0%
<b>Expenses</b>		
Bank charges/Safekeeping fees	6'028 5.4%	3'543 0.2%
Gain/Loss on Securities	18'545 16.8%	0 0.0%
Administration costs	12'703 11.5%	8'062 0.5%
Legal- and Professional fees	11'974 10.8%	22'235 1.3%
Website expenses	65'324 59.0%	49'914 2.9%
Other expenses	4'302 3.9%	8'006 0.5%
General Meeting costs	2'717 2.5%	69'923 4.1%
Donations	37'159 33.6%	0 0.0%
Tax payments	0 0.0%	8'000 0.5%
<b>General expenses</b>	<b>158'750 143.4%</b>	<b>169'683 9.9%</b>
Meeting Milan	0 0.0%	1'041'502 60.8%
Awards granted	0 0.0%	11'328 0.7%
Exchange difference	15'403 13.9%	0 0.0%
<b>Total Expenses</b>	<b>174'153 157.4%</b>	<b>1'222'513 71.4%</b>
<b>Total EXPENDITURE</b>	<b>534'603 483.0%</b>	<b>1'222'513 71.4%</b>
<b>Profit / Loss</b>	<b>-423'929 -383.0%</b>	<b>490'477 28.6%</b>
<b>Net assets at end of period</b>	<b>1'615'479</b>	<b>2'039'409</b>

# 3. TREASURER'S REPORT *(M. Burnier)*

## Foundation of the ESH, 6300 Zug

### Income and Expenditure as per 30.09.2018 (provisional, not audited)

	30.09.2018 (CHF)		31.12.2017 (CHF)	
<b>Net assets at beginning of period</b>	<b>268'285</b>		<b>344'022</b>	
<b>INCOME</b>				
Allowance to the FESH	<b>360'450</b>	93.2%	<b>0</b>	0.0%
<b>Other income</b>				
Contribution to Educational Meeting	0		5'851	23.0%
Subscriptions of organisations	25'193	6.5%	6'490	25.5%
Dividend/Interest Securities	929	0.2%	902	3.5%
General Meeting income	0	0.0%	2'324	9.1%
Exchange difference	0	0.0%	9'924	38.9%
<b>Total Other income</b>	<b>386'572</b>	100.0%	<b>25'490</b>	100.0%
<b>Total INCOME</b>	<b>386'572</b>	100.0%	<b>25'490</b>	100.0%

# 3. TREASURER'S REPORT *(M. Burnier)*

## Foundation of the ESH, 6300 Zug

### Income and Expenditure as per 30.09.2018 (provisional, not audited)

	30.09.2018 (CHF)		31.12.2017 (CHF)	
<b>Net assets at beginning of period</b>	<b>268'285</b>		<b>344'022</b>	
<b>INCOME</b>				
Allowance to the FESH	<b>360'450</b>	93.2%	<b>0</b>	0.0%
<b>Other income</b>				
Contribution to Educational Meeting	0		5'851	23.0%
Subscriptions of organisations	25'193	6.5%	6'490	25.5%
Dividend/Interest Securities	929	0.2%	902	3.5%
General Meeting income	0	0.0%	2'324	9.1%
Exchange difference	0	0.0%	9'924	38.9%
<b>Total Other income</b>	<b>386'572</b>	100.0%	<b>25'490</b>	100.0%
<b>Total INCOME</b>	<b>386'572</b>	100.0%	<b>25'490</b>	100.0%

### EXPENDITURE

#### General expenses

Bank charges/Safekeeping fees	680	0.2%	435	1.7%
Loss on Securities	1'509	0.4%	1'525	6.0%
Exchange difference	24'333	6.3%	0	0.0%
Administration costs	4'472	1.2%	21'024	82.5%
Legal- and Professional fees	3'731	1.0%	3'888	15.3%
<b>Total General expenses</b>	<b>34'725</b>	9.0%	<b>26'871</b>	105.4%

#### Meeting expenses

Summerschool, Administration	5'998	1.6%	261	1.0%
Summerschool, Travel	8'843	2.3%	14'190	55.7%
Summerschool, Accommodation	95'379	24.7%	48'053	188.5%
Summerschool, Faculty Members	23'615	6.1%	0	0.0%
<b>Summer School expenses</b>	<b>133'835</b>	34.6%	<b>62'504</b>	245.2%
Educ. Meeting, Accomodation	0	0.0%	11'851	46.5%
General Meeting costs	2'470	0.6%	0	0.0%
<b>Total Meeting expenses</b>	<b>136'305</b>	35.3%	<b>74'355</b>	291.7%
<b>Total EXPENDITURE</b>	<b>171'031</b>	44.2%	<b>101'227</b>	397.1%

#### Profit / Loss

	<b>215'541</b>	55.8%	<b>-75'737</b>	-297.1%
--	----------------	-------	----------------	---------

#### Net assets at end of period

	<b>483'827</b>		<b>268'285</b>	
--	----------------	--	----------------	--

# 4. STATUS ESH BY-LAWS

*(R. Kreutz)*

BY-LAWS

ARTICLE I

**European Society of Hypertension (ESH), Zug (CH)**

The name of this organization shall be the European Society of Hypertension (ESH) and the abbreviation ESH is used in this document to refer to this organization. The ESH is a society according to art. 60 et seq. of the Swiss Civil Code. Its seat is in Zug, Switzerland.

ARTICLE II

**Purpose**

The objectives of the Society shall be to promote and encourage the advancement of scientific research and knowledge in hypertension and associated diseases. It shall also be to promote and encourage application of the knowledge to medical care in all aspects of hypertension and associated diseases. Specifically:

1. The ESH will encourage, promote, endorse or organize high quality international scientific activities and communications of the results. Such activities shall be carried out primarily by an annual European Meeting as well as through the organization, participation and co-organization of special scientific and educational meetings worldwide. They shall also be carried out by means of special publications. Research projects may be sponsored or conducted under the special circumstances appropriate to international scientific bodies.
2. The ESH will encourage, promote, endorse or organize activities involved with continuing medical education in the field of hypertension and associated diseases. This will be done also in conjunction with other scientific societies and members of health care professions.
3. The ESH will encourage, promote, endorse or organize, alone or in conjunction with other scientific societies and members of health delivery professions, postgraduate training and international exchange of investigators, teachers, fellows and students.
4. The ESH supports a Foundation (FESH) in order to achieve its purpose, especially but not limited to grant financial assistance for educational and research purposes. The ESH shall donate to FESH any surplus which are not necessary for achieving its purpose.
5. The duration of the ESH is undetermined.

ARTICLE III

**Members**

1. Membership in the ESH is open to physicians and any health care professionals worldwide who are dedicated to research in hypertension, or prevention and treatment (management) of hypertension and associated diseases.
2. Election of Members. Applicants are required to apply online at the website of the ESH and are requested to provide:
  - a) a short curriculum vitae (CV) in English (listing academic degrees and professional positions);

1



STATUTEN

ART. I

Name, Sitz

Unter dem Namen European Society of Hypertension (Europäischer Verein zur Förderung der wissenschaftlichen Forschung im Bereich des Bluthochdrucks), im folgenden Text als ESH benannt, besteht mit Sitz in Zug, Schweiz, ein Verein gemäß Art. 60ff.ZGB.

ART. II

Zweck

Der Verein bezweckt die Förderung und Unterstützung der wissenschaftlichen Forschung und der Kenntnisse im Bereich Bluthochdruck und assoziierten Erkrankungen. Er soll auch die Umsetzung dieser Kenntnisse bei der medizinischen Betreuung von Patienten im Bereich Bluthochdruck und den damit assoziierten Erkrankungen fördern und unterstützen.

Inbesondere:

1. Der Verein fördert, unterstützt, begünstigt und organisiert anspruchsvolle internationale wissenschaftliche Tätigkeiten sowie die Bekanntgabe deren Ergebnisse. Solche Tätigkeiten finden in erster Linie im Rahmen einer jährlichen Europäischen Versammlung statt sowie durch die Teilnahme an und Mitorganisation von internationalen Tagungen weltweit. Diese Aktivitäten umfassen weiterhin Publikationen. Die finanzielle Unterstützung oder Durchführung von Forschungsprojekten soll gemäß den für internationale wissenschaftliche Organisationen geeigneten Bedingungen erfolgen.

2. Der Verein fördert, unterstützt, begünstigt und organisiert Tätigkeiten, welche mit der medizinischen Weiterbildung im Bereich Bluthochdruck und den damit verbundenen Erkrankungen in Verbindung stehen. Dies erfolgt in Zusammenarbeit mit anderen wissenschaftlichen Organisationen sowie mit Mitgliedern von medizinischen Berufen.

3. Allein oder in Zusammenarbeit mit anderen wissenschaftlichen Organisationen und Mitgliedern von medizinischen Berufen fördert, unterstützt, begünstigt und organisiert der Verein die Weiterbildung von Personen, welche den Bachelor-Abschluss besitzen, sowie internationale Austauschaufenthalte von Forschern, Lehrern, medizinischen Mitarbeitern, und Studierenden.

4. Der Verein unterstützt um seine Ziele zu verfolgen, eine Stiftung (FESH), welche insbesondere, aber nicht ausschließlich, finanzielle Unterstützung zur

Weiterbildung und zur wissenschaftlichen Forschung leisten soll. Der Verein wendet allfällige, nicht für Vereinszwecke benötigte finanzielle Überschüsse der von ihm errichteten Stiftung zu.

5. Der Verein besteht auf unbeschränkte Dauer.

- 1 -




**KOPIE**

Anmeldung

Zur Eintragung in das Handelsregister wird folgendes angemeldet:

0. Unternehmungsidentifizierung
- 0.1.1. **Firma**  
European Society of Hypertension
- 0.1.2. **Übersetzungen der Firma**
- 0.2. **Sitz**  
c/o lic. iur. Urs J. Hausheer, Untermüli 6, 6302 Zug
- 0.3. **Kurzzweck**  
Förderung und Unterstützung der wissenschaftlichen Forschung und der Kenntnisse im Bereich Bluthochdruck
- 0.4. **Rechtsform**  
Verein
- 0.5. **SHAB-Zitat**  
(SHAB Nr. 56 vom 21.03.2002, S. 19, TB-Nr. 2776)
- 1.0.5. **Statutenänderung**  
10. Juni 2018
16. **Gebühren**
17. **Belege**
  1. Anmeldung
  2. Vereinsversammlungsprotokoll
  3. Statuten
18. **Gebührendressat**  
Domizil der Gesellschaft
- 19.1. **Bestellungen**  
2 Handelsregistrauszüge
- 19.2. **Lieferung an**  
Domizil der Gesellschaft
20. **Registerhinweise**  
--
- 21.0 **Ort und Datum**  
Zug, 6. August 2018

  
European Society of Hypertension  
Reinhold Kreuz



# 5. ESH COUNCIL MEMBERS

*(K. Tsioufis, R. Kreutz)*

## a. END OF TERM MEMBERS

- a. Regular members
- b. Ex-officio
- c. Special officers

## b. NOMINATION NEW MEMBERS

# By-laws: Council-Members- **ARTICLE IV**

2. The ESH Scientific Council is formed **by 11 elected members (including office bearers), by non-voting ex-officio members and by non-voting Executive officers** nominated by the Council for specific matters

## **Members:**

1. Elected voting members (n=11)
2. Non-voting Ex-Officio members
3. Non-voting Executive Officers

# 1. Elected ESH –Council Members

By-laws IV.2.

	A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P
1		2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
2	P Van de Borne	Start June								End June						
3	K Tsioufis							President	ImmPastPres	End June						
4	E Agabiti Rosei			Start June		President		ImmPastPres	End June			End June				
5	M Azizi			Start June								End June				
6	B Belakovic			Start June								End June				
7	T Kahan					Start June								End June		
8	B Williams					Start June								End June		
9	K Reinhold					Start June								End June		
10	E Lurbe					Start June								End June		
11	M Bochud					Start June								End June		
12	A Januszewics						Start June								End June	
13	J Polonia						Start June								End June	

Members leaving the Council in June 2019:

1. P. Van de Borne
2. E. Agabiti Rosei
3. M. Bochud per personal request

Change in office bearers:

1. K. Tsioufis end of term as President June 2019
2. E. Agabiti Rosei end of term immediate Past President

# 1. Selection of New Elected ESH –Council Members

- Open for Discussion:
  - Geographical representation
  - Potential activities, prospective needs for the Council
    - e.g. filling positions of office bearers:
      - President, Vice-president
      - Treasurer
      - Secretary,
      - Officer at Large,
  - Other aspects? , area of expertise,

## 2. Ex-Officio Council Members

By-laws IV.3.

Ex-Officio non-voting members of the Scientific ESH Council are:

- a. one ESH member designated by the International Society of Hypertension
- b. one ESH member representing FESH**
- c. one ESH member representing National Hypertension Societies

**The ex-officio member shall serve for a two-year term with the option to renew the appointment for two more years**

### 3. Executive Officers in the Council By-laws IV.6.

- The ESH Scientific Council may appoint executive officers with specific responsibilities in areas that are regarded by the ESH Scientific Council to require expert attention and decisions on a continuous basis. They can be selected from among ESH Scientific Council members, regular ESH members or non-members on account of experience and competence. Executive officers selected from regular ESH members or non-members will normally be invited by the ESH president to attend the ESH Scientific Council meeting or a portion of the meeting but may not vote or be elected to position of office bearers. Areas to be considered for executive officer appointments are:
  - a. Clinical Hypertension Specialist activities (currently M.Azizi)
  - b. ESH excellence centres (currently B.Jelacovic)
  - c. Coordination of Working Group activities (currently G. Parati)
  - d. ESH Summer Schools (currently R. Cifková)
  - e. Educational/Research activities of the Society (currently G. Mancia)
  - f. Liaison with other national hypertension societies and World Hypertension League
    - a. D. Clement (contacts with EU officers)
    - b. A. Coca (Representative for Latin America Relations)
    - c. A. Manolis (Representative for Middle East Relations)
    - d. E. Agabiti Rosei (Representative for Far East Relations)

**The Executive officers shall serve for a two-year term with the option to renew the appointment for two more years**

## 6. ESH RESEARCH PROJECTS

- a. ESH BP CONTROL STUDY (*B. Jelakovic, K. Tsioufis*)
- b. ESH APP PILOT STUDY (*K. Tsioufis*)
- c. *ESH Emergency BP project (K. Tsioufis)*

## ESH BP CONTROL STUDY (*B. Jelakovic, K. Tsioufis*)

- Overview of current status – B. Jelakovic
- National contact persons (ESH Council members) for the project
- Scientific Steering Committee
  - B. Jelakovic, K. Tsioufis, E Agabiti Rosei, G. Mancia, R. Kreutz, J. Polonia, A. Januszewicz



# Blood Pressure Control in ESH Excellence Centers

## **BP-CON-ESH**

Study of the ESH on Blood Pressure Control in ESH Excellence Centers

*dedicated to*  
*Professor Alberto Zanchetti*





**Items we discussed in Barcelona:**

1.The budget plan

2.Safety of data

3.Steering and safety committee



## What is done:

1. So far 98 Excellence centers confirmed participation  
34 countries, 2 out of Europe
2. eCRF is ready for use, it is placed at our website.
3. Omron delivered M7 devices (400) to Croatia and we started with shipment to Excellence centers.
4. Project protocol and materials for local ethical boards were sent to all participating centers.



<b>ALBANIA (1)</b>	Service of Internal Medicine and Hypertension, UHC Mother Teresa, Tirana	Dr. Tase, Mihal	<a href="mailto:mihaltase@hotmail.com">mihaltase@hotmail.com</a>
<b>ARGENTINA (1)</b>	Centro de Hipertensión Arterial del Hospital Universitario Austral, Buenos Aires	Prof. Kotliar, Carol	<a href="mailto:ckotliar@gmail.com">ckotliar@gmail.com</a>
<b>ARMENIA (1)</b>	Center of Preventive Cardiology, Yerevan	Dr. Zelveian, Parounak	<a href="mailto:zelveian@hotmail.com">zelveian@hotmail.com</a>
<b>AUSTRIA (2)</b>	Cardiology Department Klinikum Wels-Frieskirchen, Wels	Dr. Eber, Bernd Christian	<a href="mailto:bernd.eber@klinikum-wels.at">bernd.eber@klinikum-wels.at</a>
<b>BELGIUM (5)</b>	Univ. Klinikum LKH/Cardiology, Graz	Prof. Zweiker, Robert	<a href="mailto:robert.zweiker@gmail.com">robert.zweiker@gmail.com</a>
	Centre Universitaire d'approche diagnostique et thérapeutique de l'hypertension artérielle CHU de Liège, Liège Sart Tilman	Prof. Krzesinski, Jean-Marie	<a href="mailto:jm.krzesinski@chu.ulg.ac.be">jm.krzesinski@chu.ulg.ac.be</a>
	Department of Nephrology and Hypertension, Universitair Ziekenhuis Brussels	Dr. Van der Niepen, Patricia	<a href="mailto:hemoვნnp@uzbrussel.be">hemoვნnp@uzbrussel.be</a>
	Hypertension Clinic Erasme Hospital, Brussels	Prof. van de Borne, EHS <sup>®</sup> , Philippe	<a href="mailto:philippe.van.de.borne@erasme.ulb.ac.be">philippe.van.de.borne@erasme.ulb.ac.be</a>
	Hypertension Clinic, Cliniques Universitaires Saint-Luc (UCL), Brussels	Prof. Persu, EHS <sup>®</sup> , Alexandre	<a href="mailto:alexandre.persu@card.ucl.ac.be">alexandre.persu@card.ucl.ac.be</a>
<b>BOSNIA &amp; HERZEGOVINA (1)</b>	UZ Gent Hypertension Excellence, Centre, Ghent	Prof. De Backer, Tine	<a href="mailto:tine.debacker@ugent.be">tine.debacker@ugent.be</a>
	<b>BULGARIA (1)</b>	Centar za Hipertenziju, Sarajevo	Prof. Solokovic, Sekib
	University Hospital "St. Anna", Sofia	Prof. Raev, Dimitar	<a href="mailto:draevbg56@yahoo.com">draevbg56@yahoo.com</a>

<b>CROATIA (1)</b>	Center for Hypertension, University of Zagreb, Zagreb	Prof. Jelakovic, EHS <sup>®</sup> , Bojan	<a href="mailto:jelakovicbojan@gmail.com">jelakovicbojan@gmail.com</a>
<b>CZECH REPUBLIC (4)</b>	Center for Arterial Hypertension and Vascular Health, Charles University Medical School and University Hospital, Pilsen	Prof. Filipovský EHS <sup>®</sup> , Jan	<a href="mailto:filipovsky@fnplzen.cz">filipovsky@fnplzen.cz</a>
	Center for Hypertension, Charles University, Prague	Prof. Widimsky Jr., Jiri	<a href="mailto:jwidi@lf1.cuni.cz">jwidi@lf1.cuni.cz</a>
	Institute for Clinical and Experimental Medicine (IKEM) and Thomayer Hospital, Prague	Prof. Cifkova, EHS <sup>®</sup> , Renata	<a href="mailto:renata.cifkova@ftn.cz">renata.cifkova@ftn.cz</a>
	University Hospital, Olomouc	Prof. Václavík, Jan	<a href="mailto:vaclavik.j@centrum.cz">vaclavik.j@centrum.cz</a> <a href="mailto:hypertenze@centrum.cz">hypertenze@centrum.cz</a> <a href="mailto:mho@dadlnet.dk">mho@dadlnet.dk</a>
<b>DENMARK (1)</b>	Hypertension Clinic, Holbaek University Hospital, Holbaek	Prof. Olsen, EHS <sup>®</sup> , Michael	
<b>ESTONIA (1)</b>	Tallinn Hypertension Excellence Centre, Tallinn	Prof. Viigimaa, EHS <sup>®</sup> , Margus	<a href="mailto:margus.viigimaa@regionaalhaigla.ee">margus.viigimaa@regionaalhaigla.ee</a>
<b>FRANCE (6)</b>	Hypertension Unit, Hospital Europeen Georges Pompidou, Paris	Prof. Azizi, EHS <sup>®</sup> , Michel	<a href="mailto:michel.aziz@egp.aphp.fr">michel.aziz@egp.aphp.fr</a>
	Service de Cardiologie, Hospital de la Croix-Rousse, Hospices Civils de Lyon, Lyon	Dr. Lantelme, EHS <sup>®</sup> , Pierre	<a href="mailto:pierre.lantelme@chu-lyon.fr">pierre.lantelme@chu-lyon.fr</a>
	Tours University Hospital Hypertension Center, Tours	Dr. Halimi, EHS <sup>®</sup> , Jean-Michel	<a href="mailto:halimi@med.univ-tours.fr">halimi@med.univ-tours.fr</a>
	UF Hypertension et Athérombose Service de Cardiologie - Pôle Thorax et Vaisseaux CHU Michallon, Grenoble	Dr. Ormezzano, Olivier	<a href="mailto:oormezzano@chu-grenoble.fr">oormezzano@chu-grenoble.fr</a>
	Unité d'Hypertension Artérielle - Hôpital Avicenne, Bobigny	Prof. Mourad, EHS <sup>®</sup> , Jean-Jacques	<a href="mailto:jean-jacques.mourad@avc.aphp.fr">jean-jacques.mourad@avc.aphp.fr</a>
	Unité Hypertension Artérielle, University Hospital of Bordeaux, Bordeaux	Dr. Gosse, EHS <sup>®</sup> , Philippe	<a href="mailto:philippe.gosse@chu-bordeaux.fr">philippe.gosse@chu-bordeaux.fr</a>

**GERMANY (6)**

Centre of Nephrology, Goettingen Dr Schulz, EHS<sup>®</sup>, Egbert  
Hypertension Center Munich, Prof. Middeke, Martin  
Munich

[eg.schulz@nz-goe.de](mailto:eg.schulz@nz-goe.de)  
[martin.middeke@gmx.de](mailto:martin.middeke@gmx.de)

Hypertension Center Berlin Charité, Prof. Scholze, EHS<sup>®</sup>, Juergen  
Berlin

[juergen.scholze@yahoo.de](mailto:juergen.scholze@yahoo.de)

Hypertoniezentrum Marburg - Prof. Kreutz, EHS<sup>®</sup>, Reinhold  
Klinik für Inner Medizin und Dr Hoyer, EHS<sup>®</sup>, Joachim  
Nephrologie, Marburg

[reinhold.rreutz@charite.de](mailto:reinhold.rreutz@charite.de)  
[hoyer@med.uni-marburg.de](mailto:hoyer@med.uni-marburg.de)

Universitätskliniken des Saarlandes, Dr. Böhm, Michael  
Homburg/Saar

[michael.boehm@uks.eu](mailto:michael.boehm@uks.eu)

Universiy Hypertension Centre, Prof. Reuter, Hannes  
Cologne

[hannes.reuter@uk-koeln.de](mailto:hannes.reuter@uk-koeln.de)

**GREECE (17)**

Cardiology Dept. of Heraklion Dr. Marketou, Maria  
University Hospital, Heraklion

[maryemarke@yahoo.gr](mailto:maryemarke@yahoo.gr)  
[cardio@med.uoc.gr](mailto:cardio@med.uoc.gr)

Hypertension Center, Department Dr. Sarafidis, Pantelis  
of Nephrology, Hippokration  
Hospital, Aristotle University of  
Thessaloniki

[psarafidis11@yahoo.gr](mailto:psarafidis11@yahoo.gr)

Hypertension Center, Department Dr Kalaitzidis, Rigas  
of Nephrology, University Hospital  
of Ioannina

[rigaska@gmail.com](mailto:rigaska@gmail.com)

Hypertension Unit, Department of Dr Papadakis, Ioannis  
Internal Medicine, University  
Hospital of Heraklion

[papadakisja@hotmail.com](mailto:papadakisja@hotmail.com)

Hypertension and Cardiovascular Dr Andreadis, EHS<sup>®</sup>, Emmanuel  
Prevention Clinic, 3rd Department  
of Medicine, Evangelismos  
Hospital, Athens

[andreadise@ath.forthnet.gr](mailto:andreadise@ath.forthnet.gr)

Hypertension Center of Sotiria Dr. Achimastos, EHS<sup>®</sup>, Apostolos  
Hospital, Athens Prof. Stergiou, EHS<sup>®</sup>, George S.

[achimas@hellasnet.gr](mailto:achimas@hellasnet.gr)  
[gstergi@med.uoa.gr](mailto:gstergi@med.uoa.gr)

Hypertension Centre, Department Dr Zakopoulos, Nikolaos  
of Clinical Therapeutics, Medical  
School of Athens, Alexandra  
Hospital, Athens

[nzakop@med.uoa.gr](mailto:nzakop@med.uoa.gr)

Hypertension Clinic, Cardiology Prof. Manolis, EHS<sup>®</sup>, Athansios  
Department, Asklepeion Hospital,  
Athens

[ajmanol@otenet.gr](mailto:ajmanol@otenet.gr)



<b>GREECE (17)</b>	Cardiology Dept. of Heraklion University Hospital, Heraklion Hypertension Unit, 2nd Department of Cardiology, Medical School University of Athens, ATTIKON Hospital, Athens	Dr. Marketou, Maria	<a href="mailto:maryemarke@yahoo.gr">maryemarke@yahoo.gr</a>
	Hypertension Unit, "Elena Venizelou" General & Maternity Hospital, Athens	Dr. Triantafyllidi, EHS <sup>®</sup> , Helen	<a href="mailto:cardio@med.uoc.gr">cardio@med.uoc.gr</a> <a href="mailto:seliani@hotmail.com">seliani@hotmail.com</a>
	Hypertension-24h ABPM Center, Papageorgiou Hospital, Nea Efkarpia	Dr. Makris, EHS <sup>®</sup> , Thomas Dr. Thomopoulos, Costas	<a href="mailto:makelena@yahoo.gr">makelena@yahoo.gr</a> <a href="mailto:tholos@otenet.gr">tholos@otenet.gr</a>
<b>HUNGARY (4)</b>		Prof. Kotsis, EHS <sup>®</sup> , Vasilios	<a href="mailto:bkotsis@med.uoa.gr">bkotsis@med.uoa.gr</a>
	First Department of Internal Medicine, Medical and Health Science Centre, University of Debrecen, Debrecen	Dr. Pall, Dénes	<a href="mailto:pall.denes@gmail.com">pall.denes@gmail.com</a>
	Jósa András Teaching Hospital, Nyíregyháza	Dr. Szegedi, János	<a href="mailto:szegedi@josa.hu">szegedi@josa.hu</a>
	St. Imre Teaching Hospital, Budapest	Prof. Farsang, Csaba Prof. Kis, EHS, Istvan	<a href="mailto:hunghyp@t-online.hu">hunghyp@t-online.hu</a> <a href="mailto:istvan.kiss@enternet.hu">istvan.kiss@enternet.hu</a>
<b>ISRAEL (1)</b>	University of Pécs, Regional Hypertension Centre, Pécs	Prof. Kovacs, Tibor	<a href="mailto:tibor.kovacs@aok.pte.hu">tibor.kovacs@aok.pte.hu</a>
	Hypertension Institute, Wolfson Medical Center (Associated Centre), Holon	Prof. Zimlichman, Reuven	<a href="mailto:zimlich@post.tau.ac.il">zimlich@post.tau.ac.il</a>

ITALY (13)

<p>Ambulatorio Ipertensione, Ospedale Niguarda, Dip. De Gasperis e Università di Milano Bicocca, Milano Centre for the Diagnosis and Treatment of Arterial Hypertension, Division of Cardiology, II Faculty of Medicine, University of Rome "La Sapienza", Rome</p>	<p>Prof. Giannattasio EHS<sup>®</sup>, Cristina Prof. Volpe, EHS<sup>®</sup>, Massimo</p>	<p><b>BP-CON-ESH</b> <a href="mailto:cristina.giannattasio@unimib.it">cristina.giannattasio@unimib.it</a> <a href="mailto:cristina.giannattasio@ospedaleniguarda.it">cristina.giannattasio@ospedaleniguarda.it</a> <a href="mailto:massimo.volpe@uniroma1.it">massimo.volpe@uniroma1.it</a> <a href="mailto:centro.ipertensione@ospedalesanandrea.it">centro.ipertensione@ospedalesanandrea.it</a></p>
<p>Centre of Prevention and Treatment of Arterial Hypertension and Cardiovascular Risk Factors, Brescia</p>	<p>Prof. Agabiti Rosei, EHS<sup>®</sup>, Enrico</p>	<p><a href="mailto:enrico.agabitirosei@unibs.it">enrico.agabitirosei@unibs.it</a></p>
<p>Centro Ipertensione e Malattie Cardiovascolari, Ancona</p>	<p>Prof. Sarzani, Riccardo</p>	<p><a href="mailto:sarzani@univpm.it">sarzani@univpm.it</a></p>
<p>Centro per lo Studio e la Cura della Ipertensione Arteriosa IRCCS AOU San Martino, Genova</p>	<p>Prof. Pontremoli, EHS<sup>®</sup>, Roberto</p>	<p><a href="mailto:roberto.pontremoli@unige.it">roberto.pontremoli@unige.it</a></p>
<p>Centro per lo Studio e la Cura dell'Ipertensione Arteriosa, University of Bologna, Bologna</p>	<p>Prof. Borghi, EHS<sup>®</sup>, Claudio</p>	<p><a href="mailto:claudio.borghi@unibo.it">claudio.borghi@unibo.it</a></p>
<p>Centro Studi Ipertensione e Malattie Vascolari, Istituto Clinico Universitario, Verano Brianza</p>	<p>Prof. Mancia, EHS<sup>®</sup>, Giuseppe Dr. Filippo Scalise</p>	<p><a href="mailto:giuseppe.mancia@unimib.it">giuseppe.mancia@unimib.it</a></p>
<p>Clinica Medica Ospedale San Gerardo, Monza</p>	<p>Prof. Grassi, EHS<sup>®</sup>, Giudo</p>	<p><a href="mailto:giudo.grassi@unimib.it">giudo.grassi@unimib.it</a></p>
<p>Excellence Centre of Hypertension, Department of Medical Sciences, University of Torino, Torino</p>	<p>Prof. Veglio, EHS<sup>®</sup>, Franco</p>	<p><a href="mailto:franco.veglia@unito.it">franco.veglia@unito.it</a> <a href="mailto:centroiperten.torino@libero.it">centroiperten.torino@libero.it</a></p>
<p>Hypertension Centre and Internal Medicine Unit, Santa Maria della Misericordia General Hospital, Rovigo</p>	<p>Prof. Mazza, Alberto</p>	<p><a href="mailto:alberto.mazza@aulss5.veneto.it">alberto.mazza@aulss5.veneto.it</a></p>
<p>Napoli Hypertension Excellence Centre, Federico II Clinic Research</p>	<p>Prof. De Luca, Nicola Prof. Strazzullo, Pasquale</p>	<p><a href="mailto:nicola.deluca@unina.it">nicola.deluca@unina.it</a> <a href="mailto:strazzul@unina.it">strazzul@unina.it</a></p>
<p>Center for Hypertension and Related Conditions, Napoli</p>	<p>Prof. Trimarco, EHS<sup>®</sup>, Bruno</p>	<p><a href="mailto:trimarco@unina.it">trimarco@unina.it</a></p>
<p>Regional Centre of Hypertension and Hydroelectrolytic Metabolism of Reggio Calabria, Reggio Calabria</p>	<p>Dr. Mallamaci, Francesca</p>	<p><a href="mailto:francesca.mallamaci@libero.it">francesca.mallamaci@libero.it</a></p>
<p>S. Luca Hospital, Istituto Auxologico Italiano, Milano</p>	<p>Prof. Parati, EHS<sup>®</sup>, Gianfranco</p>	<p><a href="mailto:gianfranco.parati@unimib.it">gianfranco.parati@unimib.it</a></p>





<b>LATVIA (1)</b>	Latvian Centre of Cardiology, Paulus Stadins Clinical University Hospital, Riga	Dr. Erglis, Andrejs	<a href="mailto:a.a.erglis@stradini.lv">a.a.erglis@stradini.lv</a>
<b>LEBANON (2)</b>	American University Center, Hypertension/Vascular Medicine Division (Associated Centre), Beirut	Dr. Barbari, EHS <sup>®</sup> , Abdel	<a href="mailto:ab01@aub.edu.lb">ab01@aub.edu.lb</a>
	Hypertension & Vascular Institute (Associated Centre), Beirut	Prof. Asmar, Roland	<a href="mailto:ra@cmcv.org">ra@cmcv.org</a> <a href="mailto:contacthvi@hopital-libanais.com">contacthvi@hopital-libanais.com</a>
<b>LITHUANIA (1)</b>	Kaunas Hypertension Excellence Centre, Kaunas	Prof. Slapikas, Rimvydas	<a href="mailto:rimvydas.slapikas@kmuk.lt">rimvydas.slapikas@kmuk.lt</a>
<b>NETHERLANDS (2)</b>	Department of Medicine, Radboud University of Nijmegen Medical Center, Nijmegen	Dr. Deinum, EHS <sup>®</sup> , Jacob	<a href="mailto:j.deinum@aig.umcn.nl">j.deinum@aig.umcn.nl</a>
	University Hospital Maastricht, Maastricht	Prof. De Leeuw, EHS <sup>®</sup> , Peter	<a href="mailto:p.deleeuw@maastrichtuniversity.nl">p.deleeuw@maastrichtuniversity.nl</a>
<b>POLAND (5)</b>	1st Cardiac and Hypertension Department Jagiellonian University Collegium Medicum, Krakow	Dr. Czarnecka, EHS <sup>®</sup> , Danuta	<a href="mailto:dczarnecka@su.krakow.pl">dczarnecka@su.krakow.pl</a>
	Department of Hypertension, Institute of Cardiology, Warsaw	Prof. Januszewicz, Andrzej	<a href="mailto:ajanu@op.pl">ajanu@op.pl</a>
	Department of Internal Medicine, Hypertension and Vascular Diseases, Warsaw Medical University, Warsaw	Dr. Gaciong, Zbigniew	<a href="mailto:zgaciong@hotmail.com">zgaciong@hotmail.com</a>
	Department of Nephrology, Hypertension and Internal Diseases, A. Jurasz University Hospital, Bydgoszcz	Prof. Manitius, Jacek	<a href="mailto:nerka@nerka.cpro.pl">nerka@nerka.cpro.pl</a>
	Hypertension Unit, Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk	Prof. Narkiewicz, EHS <sup>®</sup> , Krzysztof	<a href="mailto:knark@gunmed.edu.pl">knark@gunmed.edu.pl</a>
<b>PORTUGAL (1)</b>	Centro Hospitalar do Alto Ave, Minho University, Guimaraes	Prof. Cotter, EHS <sup>®</sup> , Jorge	<a href="mailto:jorgecotter@gmail.com">jorgecotter@gmail.com</a>
	Unidade de Hipertensão Arterial e Risco Cardiovascular do Hospital Pedro Hispano, Matosinhos	Prof. Polonia, Jorge Dr. Silva, José	<a href="mailto:jjpolonia@gmail.com">jjpolonia@gmail.com</a> <a href="mailto:jasilva.54@gmail.com">jasilva.54@gmail.com</a>

<b>ROMANIA (1)</b>	Department of Cardiology and Internal Medicine, Emergency Clinical Hospital of Bucharest, Bucharest	Dr. Dorobantu, EHS <sup>®</sup> , Maria	<a href="mailto:maria.dorobantu@gmail.com">maria.dorobantu@gmail.com</a>
<b>RUSSIA (1)</b>	Russian Cardio Research Centre	Prof. Boytsov, Sergey	<a href="mailto:sboytsov@gnicpm.ru">sboytsov@gnicpm.ru</a>
<b>SERBIA (2)</b>	Centre for Hypertension of the Clinical Centre of Serbia, Belgrade Clinic for Internal Disease InterMedica, Nis	Dr. Stojanov, EHS <sup>®</sup> , Vesna Prof. Lovic, EHS <sup>®</sup> , Dragan	<a href="mailto:stojanovves@eunet.rs">stojanovves@eunet.rs</a> <a href="mailto:draganl1@sbb.rs">draganl1@sbb.rs</a>
<b>SLOVAK REPUBLIC (1)</b>	Slovak National Centre of Hypertension, Department of Cardiology, National Institute of Cardiovascular Diseases, Bratislava	Dr. Filipova, EHS <sup>®</sup> , Slavomira Dr. Kultétyová, Dana	<a href="mailto:filipova@nusch.sk">filipova@nusch.sk</a> <a href="mailto:dana.skultetyova@nusch.sk">dana.skultetyova@nusch.sk</a>
<b>SLOVENIA (1)</b>	University Medical Centre Ljubljana, Department of Hypertension, Dr. Peter Drzaj Hospital, Ljubljana	Dr. Brguljan, Jana	<a href="mailto:jana.brguljan-hitij@guest.arnes.si">jana.brguljan-hitij@guest.arnes.si</a>
<b>SPAIN (6)</b>	Hypertension Clinic, Internal Medicine, Hospital Clinico, University of Valencia, Valencia Hypertension Clinic, Nephrology Department, Reina Sofia University Hospital, Cordoba Hipertensión Clinic, Internal Medicine, Hospital Clinico, University of Barcelona Hypertension Unit-Hospital del Mar, Barcelona Pediatric Nephrology Clinic, Department of Pediatrics, Concorcio Hospital General Universitario, University of Valencia, Valencia	Prof. Redon, EHS <sup>®</sup> , Josep Dr. Santamaría, Rafael Dr. Cristina Sierra Dr. Oliveras Serrano, EHS <sup>®</sup> , Anna Prof. Lurbe, Empar	<a href="mailto:josep.redon@uv.es">josep.redon@uv.es</a> <a href="mailto:rsantamariao@gmail.com">rsantamariao@gmail.com</a> <a href="mailto:csierra@clinic.ub.e">csierra@clinic.ub.e</a> <a href="mailto:aoliveras@hospitaldelmar.cat">aoliveras@hospitaldelmar.cat</a> <a href="mailto:empar.lurbe@uv.es">empar.lurbe@uv.es</a>
	Unidad de Hipertensión, Hospital Infanta Cristina, Badajoz	Prof. Robles Perez-Monteoliva, EHS <sup>®</sup> , Nicolas Roberto	<a href="mailto:nrrobles@yahoo.es">nrrobles@yahoo.es</a> <a href="mailto:unidadhtabadajoz@gmx.es">unidadhtabadajoz@gmx.es</a>
<b>SWEDEN (1)</b>	Danderyd University Hospital, Stockholm	Prof. Kahan, EHS <sup>®</sup> , Thomas	<a href="mailto:kahan@ds.se">kahan@ds.se</a>
<b>SWITZERLAND (1)</b>	University Institute of Social and Preventive Medicine in Lausanne	Prof. Bochud, Murielle Prof. Sudano, Isabella	<a href="mailto:murielle.bochud@chuv.ch">murielle.bochud@chuv.ch</a> <a href="mailto:isabella.sudano@usz.ch">isabella.sudano@usz.ch</a>

# BP-CON-ESH





<b>TURKEY (1)</b>	Istanbul University Cerrahpaşa School of Medicine, Istanbul	Prof. Erdine, EHS <sup>®</sup> , Serap	<a href="mailto:eserdine@superonline.com">eserdine@superonline.com</a>
<b>UKRAINE (1)</b>	National Scientific Center "The M.D. Strazhesko Institute of Cardiology", Kyiv	Dr. Sirenko, EHS <sup>®</sup> , Yuriy	<a href="mailto:sirenkoyu@gmail.com">sirenkoyu@gmail.com</a>
<b>UNITED KINGDOM (6)</b>	BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow	Prof. Dominiczak, EHS <sup>®</sup> , Anna	<a href="mailto:anna.dominiczak@glasgow.ac.uk">anna.dominiczak@glasgow.ac.uk</a>
	Blood Pressure Unit & Centre for Microcirculatory Research, London	Dr. Antonios, Tarek	<a href="mailto:t.antonios@sgul.ac.uk">t.antonios@sgul.ac.uk</a>
	Brighton & Sussex University Hospital NHS Trust, Brighton	Prof. Rajkumar, EHS <sup>®</sup> , Chakravarthi	<a href="mailto:c.rajkumar@bsms.ac.uk">c.rajkumar@bsms.ac.uk</a>
	Leicester Hypertension Service, Leicester Royal Infirmary, Leicester	Prof. Williams, Bryan	<a href="mailto:bw17@le.ac.uk">bw17@le.ac.uk</a>
	The Pearl-Rose Clinic (Hypertension & Cardiovascular Risk), Hammersmith Hospital, London	Dr Chapman, Neil	<a href="mailto:neil.chapman1@nhs.net">neil.chapman1@nhs.net</a>
	Williamo Harvey Research Institute, Department of Clinical Pharmacology, Queen Mary and Wesfield College, St. Bartholomew's Royal London School of Medicine & Dentistry, London	Dr. Lobo, EHS <sup>®</sup> , Melvin	<a href="mailto:m.d.lobo@qmul.ac.uk">m.d.lobo@qmul.ac.uk</a>



## Non-participants

### Europe

Belarus

Finland

Luxembourg

Norway

### Out of Europe

Australia

Bahrain

China

Venezuela



# BP-CON ESH – early starters

8 countries; 10 Excellence centers

start November 2018

- Croatia Bojan Jelaković- [jelakovicbojan@gmail.com](mailto:jelakovicbojan@gmail.com); Tamara Knežević [knezevic.tamara@yahoo.com](mailto:knezevic.tamara@yahoo.com)
- Greece Costas Tsioufis [ktsioufis@gmail.com](mailto:ktsioufis@gmail.com) ; Vasilios Kotisis - [bkotsis@med.uoa.gr](mailto:bkotsis@med.uoa.gr)
- Italy Gianfranco Parati - [gianfranco.parati@unimib.it](mailto:gianfranco.parati@unimib.it) ; Martino Pengo
- Germany Reinhold Kreutz - [reinhold.rreutz@charite.de](mailto:reinhold.rreutz@charite.de); Juergen Scholze - juergen. [scholze@yahoo.de](mailto:scholze@yahoo.de)
- Poland Danuta Czarnecka - [dczarnecka@su.krakow.pl](mailto:dczarnecka@su.krakow.pl)
- Romania Maria Dorobantu - [maria.dorobantu@gmail.com](mailto:maria.dorobantu@gmail.com)
- Serbia Vesna Stojanov - [stojanovves@eunet.rs](mailto:stojanovves@eunet.rs); Dragan Lovic - [draganl1@sbb.rs](mailto:draganl1@sbb.rs)
- Slovenia Jana Brguljan - [jana.brguljan-hitij@guest.arnes.si](mailto:jana.brguljan-hitij@guest.arnes.si)



Home About ESH Online Education Meetings/Events Publications Guidelines Communities Resources Contact Us

### ESH At a Glance

- Editor's Page
- Membership
- Hypertension Specialist
- Excellence Centres
- Working Groups
- National Societies
- e-Learning Programme
- Activities
- ESH Newsletters

### ESH E-LEARNING

HYPERTENSION SELF-ASSESSMENT PROGRAMME

### WORLD HYPERTENSION DAY

FRIDAY, MAY 17<sup>TH</sup>, 2019

## HYPERTENSION SPECIALIST NEWS

To maintain your Hypertension Specialist status you must be an ESH Member!

### New 2018 European Guidelines

The new "2018 European Society of Cardiology (ESC) and European Society of Hypertension (ESH) Guidelines for the management of arterial hypertension" are available for you here.

The development of the guidelines was led by Prof. Bryan Williams (ESC Chairperson), London UK, and Prof. Giuseppe Mancia (ESH Chairperson), Milan Italy, as lead authors.

[Read More »](#)

### Blood Pressure Control Study

Study of the European Society of Hypertension on Blood Pressure Control in ESH Excellence Centres, dedicated to Professor Alberto Zanchetti.

The most important task of the European Society of Hypertension is to improve blood pressure treatment and increase blood pressure control, thus decreasing cardiovascular risk, premature cardiovascular and renal morbidity and mortality, with in addition a reduction of health-care costs.

[Read More »](#)

Once you click on selected field....



**ESH Care**  
 FREE DOWNLOAD



Hypertension APP for smartphones and tablets validated & supported by the European Society of Hypertension

**CALL FMD**

DO YOU FOLLOW A COHORT OF PATIENTS WITH FMD?  
 ARE YOU WILLING TO CONTRIBUTE TO THE EUROPEAN FMD REGISTRY?

JOIN A NETWORK OF SPECIALISTS!  
 Please contact us!



European Society of Hypertension

NATIONAL SOCIETY ANNUAL MEETINGS CALENDAR



## Blood Pressure Control Study



Study of the European Society of Hypertension on Blood Pressure Control in ESH Excellence Centres dedicated to Professor Alberto Zanchetti

The most important task of the European Society of Hypertension is to improve blood pressure treatment and increase blood pressure control, thus decreasing cardiovascular risk, premature cardiovascular and renal morbidity and mortality, with in addition a reduction of health-care costs. More than a decade ago, the European Society of Hypertension established a network of Excellence Centres. Those centres are leading institutions for the diagnosis and treatment of hypertension and thus are front runners of good clinical practice in hypertension management in their countries. An important task of the Excellence Centres is also to be active in research, particularly in projects conducted by the European Society of Hypertension. The ongoing BP-CON-ESH project on the rate of blood pressure control in hypertensive patients addresses the most elementary, but at the same time the most important aspect in hypertension management, because the observed low rates of blood pressure control is the reason why hypertension is still today the leading cause of death worldwide.

In the BP-CON-ESH study we are going to include and analyze treated hypertensive patients seen consecutively by the ESH Excellence Centres. Blood pressure will be measured as usually done in the office, but care will be adopted to make measurements highly standardized in all Centres.

The primary goals will be to determine the global, regional and country rates of hypertension control in Europe. Other goals will be to identify global and regional factors associated with blood pressure control in different European regions. It is well known that the overall control of hypertension in Europe is still insufficient. However, the problem is not the same across Europe. Differences in healthcare systems exist among European countries, and in some countries government healthcare system only partially reimburse costs of antihypertensive therapy. There are also differences in gross national product, educational levels, salt consumption, prevalence of obesity and other aspects. These could cause dissimilarities in hypertension prevalence, achieved blood pressure control and cardiovascular mortality among European regions.

The results obtained in the BP-CON-ESH project will be used to refine treatment strategies for improvement of blood pressure control and will serve as a basis for assessing future changes and trends in Europe.

The BP-CON-ESH will begin in October with the first group of 9 Excellence Centres and will progressively extend to the other ESH Excellence Centres participating in the Study subsequently starting from November.

[CLICK HERE TO REGISTER](#)



Blood Pressure Control in ESH Excellence Centres (BP-CON-ESH)

Study of the European Society of Hypertension on Blood Pressure Control  
in ESH Excellence Centres

dedicated to  
Professor Alberto Zanchetti

[Home](#)

## Log In

E-mail

Password

Login

- [Click here to download printouts for BP survey user instructions](#)
- [Click here to download printouts for ESH BP CON Study flow](#)
- [Register](#) ← [Click to register](#)
- [Forgot your password?](#)





## Register

Institution

First name

Last name

E-mail

Password

*\* Password needs to be 8 characters long  
and needs to have atleast 1 number*

Confirm password

Register

*\* After registering we will send you e-mail with activation link for your account.*

- [Login](#)
- [Forgot your password?](#)

Once the Registration is completed, sign in with the previously entered data....



## Log In

E-mail

Password

Login


- [Click here to download printouts for BP survey user instructions](#)
- [Click here to download printouts for ESH BP CON Study flow](#)
- [Register](#)
- [Forgot your password?](#)


The first view of an Survey once you sign in....


## List of patient surveys

+ New Patient

Click  to EDIT PATIENT DATA

Click  to DELETE PATIENT DATA

Click  to START PATIENT SURVEY

Click  to DOWNLOAD PATIENT DATA

[Click here to download printouts for BP survey user instructions](#)

[Click here to download printouts for ESH BP CON Study flow](#)

DOWNLOAD PATIENT DATA

**Legend to all the symbols used in an App**

**Instructions and Study flow for download**

Search:

Name



Patient code



Initials



Gender




Date of birth



Added by



Action 

## Add a New Patient...

Insert new patient data ✕

First name

Last name

Initials

Gender

Date of birth

Race

Immigrant

Citizenship

Rural

Urban

## BASIC INFO ABOUT PATIENT

Marital status

Children

Educational level

Income (monthly, family)

How would you evaluate the financial condition of your household?

Job position

Health insurance

Once a New Patient is added... 1st STEP:

GENERAL INFORMATION 1   RISK FACTORS   THERAPY   CLINICAL EXAM

Patient's Initials: MK

Gender: M

Date of birth: Unkn<sup>o</sup>   Unkn<sup>o</sup>   Unknown

Race: Caucasian

Immigrant: Nonimmigrant / Resident

Citizenship: Afghanistan

Rural  
 Urban

Marital status: Unknown

Children: No

Educational level: Unknown

Income (monthly, family): Unknown

How would you evaluate the financial condition of your household?: Unknown

Job position: Unknown

Health insurance: Unknown

Next →

4 steps survey!

## 2nd STEP:

GENERAL INFORMATION 1 | **RISK FACTORS** | THERAPY | CLINICAL EXAM

**Smoking**

**Alcohol**

**Moderate drinking** no more then 2 drinks for man or no more then one drink for woman per day

**Increased drinking** more then 2 and less then 5 drinks for man per day and more then one drink and less then 5 drinks per day for woman

**Infrequent heavy drinking** more then 5 drinks per occasion rarely then once a month

**Frequent heavy drinking** more then 5 drinks per occasion,more then once a month

*\* It's possible to select multiple answers*

**Comorbidities**

- Diabetes type 1
- Diabetes type 2
- Dyslipidemia
- Coronary heart disease
- Post-MI
- Chronic heart failure
- A Fib stroke
- TIA
- Hyperuricemia
- Chronic kidney disease
- Other
- Nothing

**History of hypertension (mother)**  Yes  No

**History of hypertension (father)**  Yes  No

### 3rd STEP:

GENERAL INFORMATION RISK FACTORS **THERAPY** CLINICAL EXAM MEDICAL RECORDS

### Drugs

Antihypertensive drugs since (month/year)

Taken prescription medication in the past 30 days

Drug 1:  \* It's possible to select up to 10 drugs

Drug 2:

Drug 3:

Drug 4:

Drug 5:

Drug 6:

Drug 7:

Drug 8:

Drug 9:

Drug 10:

Drug 11:

Drug 12:

### 3rd STEP:



- Other drugs**
- Statin
  - Other antilipemic
  - Insulin
  - Oral antidiabetic
  - Warfrin
  - NOAC
  - NSAID
  - Steroids
  - Antiplatelets
  - Other

*\* It's possible to select multiple answers*

### Healthcare visits in the past year

GP visits

Specialist visits

Excellence centre visits

### Lifestyle

Physical activity

**Low** - 30 minutes walking/gardening most of days, able to talk during the activity

**Moderate** - 2-3 times per week at least 20 minutes of exercise - shortness of breath, elevated heart rate and sweating

**High** - the same activity as for moderate but more than 3 times per week, or stronger



### 3rd STEP:

week, or stronger

Since

Salt restricted diet

Weight reduction

Fruit servings per day

Vegetable servings per day

### Diagnosis

Secondary hypertension

### Procedures undergone

Renal denervation

Renovascular hypertension (RVH)

CABG

PCI stent

Surgery - suprarenal gland


Other

4th STEP:

GENERAL INFORMATION   RISK FACTORS   THERAPY   **CLINICAL EXAM**   MEDICAL RECORDS

**BP measurement technique first sequenced**   Office   *\* Office is obligatory, Unattended is optional*

**Date**  

**Time**    

**Device**   Omron (study device)

**Cuf size**   Small

**Arm**   Left

**Day when antihypertensive therapy was taken**   Don't know

**Height (cm)**   Select value

**Weight (kg)**   Select value

**Waist circumference (cm)**   Select value

**BMI**   0.00

### Casual / classic BP measurement \* all fields are obligatory

#### First BP measurement

BP mmHg

Select value

Select value

Heart rate bpm

Select value

#### Second BP measurement

BP mmHg

Select value

Select value

Heart rate bpm

Select value

#### Third BP measurement

BP mmHg

Select value

Select value

Heart rate bpm

Select value

### Unattended BP measurements \* OPTIONAL

BP mmHg

Select value

Select value

Heart rate bpm

Select value

← Previous

✓ Next

## Additional STEP - Medical records:

GENERAL INFORMATION RISK FACTORS THERAPY CLINICAL EXAM **MEDICAL RECORDS**

### Blood pressure measurements in past 6 months

First BP measurements

Date

BP mmHg

Heart rate bpm

Second BP measurements

Date

BP mmHg

Heart rate bpm

Third BP measurements

Date


BP mmHg

Heart rate bpm

ECG - to be attached

Select ECG file  No file chosen

Date



Once you've started with the Survey, it will appear an additional step - **MEDICAL RECORDS!**

# MEDICAL RECORDS:

Laboratory (if done in past 3 months)

Fasting blood glucose	<input type="text"/>	mg/dL	<input type="text"/>	mmol/L
	<input type="text"/>	mg	<input type="text"/>	mmol/L
Serum T-cholesterol	<input type="text"/>	mg/dL	<input type="text"/>	mmol/L
LDL-cholesterol	<input type="text"/>	mg/dL	<input type="text"/>	mmol/L
HDL-cholesterol	<input type="text"/>	mg/dL	<input type="text"/>	mmol/L
Triglycerides	<input type="text"/>	mg/dL	<input type="text"/>	mmol/L
Serum uric acid	<input type="text"/>	mg/dL	<input type="text"/>	μmol/L
Serum creatinine	<input type="text"/>	mg/dL	<input type="text"/>	μmol/L
eGFR (CKD-Epi)	<input type="text"/>		ml/min/1.73m <sup>2</sup>	
Microalbuminuria	<input type="text"/>	ug/L	<input type="text"/>	mg/L

24-h urine

Sodium	<input type="text"/>	mEq/24 h	<input type="text"/>	mmol/d
	<input type="text"/>	mg/24 h	<input type="text"/>	mmol/d
Potassium	<input type="text"/>	mEq/24 h	<input type="text"/>	mmol/d
	<input type="text"/>	mg/24 h	<input type="text"/>	mmol/d
Creatinine	<input type="text"/>	mg/24 h	<input type="text"/>	μmol/d
	<input type="text"/>	g/24 h	<input type="text"/>	μmol/d
	<input type="text"/>	mg/kg/24 h	<input type="text"/>	μmol/kg/d

ABPM - to be attached ( if done in last 6 months )

Select ABPM file  No file chosen

Date

Device


Once you click  
**FINISH....**


.... Your patient will be listed at the main view....


## List of patient surveys

+ New Patient

Click  to EDIT PATIENT DATA

Click  to DELETE PATIENT DATA

Click  to START PATIENT SURVEY

Click  to DOWNLOAD PATIENT DATA

[Click here to download printouts for BP survey user instructions](#)

[Click here to download printouts for ESH BP CON Study flow](#)

DOWNLOAD PATIENT DATA

Search:

Name



Patient code



Initials



Gender




Date of birth



Added by



Action 

**Field for listed patients**

- the study agreement :
  - data sharing policy
  - data management policy
  - publication policy
- nominate the steering committee
- nominate the safety committee
- budget

- put the list of European centres participating in the study at our web
- organise the core of young colleagues who will take care and be responsible for the study
  - Tamara Knezevic (Zagreb) coordinator
  - Renata will provide us with the list of participants of Summer Schools (2012-2018) and we will contact those colleagues inviting them to participate and be active in their centers (Tamara already has started).
- registration of the study

## The budget

a) eCRF and the web platform	- 10.000 Eu (already done)
b) Shipment of devices from Croatia to all other centers	- 10.000 Eu (can/will Omron cover)
c) Statistician	- 5.000 Eu (price in Croatia)
d) Costs of ethical boards	- 5,000 Eu (?)
Total	<u>30.000 Eu</u>



Objective	Activities	Milestone	Deliverables	Duration of activity
<p>1. To provide the initial technical prerequisites necessary for the project onset and to introduce all participants with procedures regarding the collection of data and anthropological measurements</p>	<p>1. <b>Preparation of questionnaires, eCRF and database for data input</b> with the addition ABPM and ECG (if decided to be incorporated into the study protocol)                  2. <b>Informing heads of all Excellence centers about the study</b>                  - introduction with the goals, work plan and protocols;                  -collecting data on feasibility of each Excellence centre: number of patients per month; number of physicians working in outpatient clinic; facilities - BP devices, cuffs, weighting platform and measurement tapes...                  3.<b>Prepare draft for Ethical approval and informed consent</b> which later should be translated and adjusted for each ESH Excellence Centre according to the local rules.                  4. <b>Development of page on the ESH web site and face book page</b>                  5. <b>Organise pilot study in one or two Excellence centers</b></p>	<p>Assurance of all requirements for research activities</p>	<p>1. Prepared questionnaires, eCRF and database for input of data                  2. Prepared code lists for centers                  3. Prepared invitation email and letters for heads of all Excellence centers                  4.Sent email and letter to all heads and get confirmation for participation                  5.Prepared Ethic committee approval and informed consent                  6.Developed web and face book page of the project                  7.Conducted pilot study in one or two (10) Excellence centers</p>	<p><b>May to October 2018</b></p> <p><b>End of pilot study February 2019</b>                  –first report Milan meeting</p>
<p>1. To collect data from all Excellence centers according to the protocol</p>	<p>1. Conducting enrollment, performing questionnaire, BP measurements, collection of all additional data; entering into eCRF.                  2.Cleaning of entered data                  3.Preparing data for statistical analysis</p>	<p>1.Conducted and finished enrollment and entering data.                  2.Data prepared for statistical analyses</p>	<p>1. Collected data from the representative sample and prepared for statistical analyses.</p>	<p>December 2018 to April 2019</p>
<p>1.To analyze data and prepared results for publishing</p>	<p>1.Conduct statistical analyses                  2.Preparing results for presentations and publishing</p>	<p>1.Statistical analyses finished                  2.Results prepared for presentation at the ESH meeting and publishing</p>	<p>1.Results prepared for presentation and publishing</p>	<p>October 2019</p>

## 6. ESH RESEARCH PROJECTS


a. ESH BP CONTROL STUDY (*B. Jelakovic, K. Tsioufis*)

a. Steering committee

b. ESH APP PILOT STUDY (*K. Tsioufis*)

c. *ESH Emergency BP project (K. Tsioufis)*

# ESH CARE app Extension Platform



**Pilot study in 6 countries**  
Greece, Germany, Belgium,  
Poland, Croatia, Serbia

# STUDY OBJECTIVES



- ❖ *To investigate whether an innovative management strategy of hypertension based on the combination of standard care plus the ESH CARE App compared to standard care improves BP control.*
- **Primary endpoint** will be differences in OBP and ABPM control rates at 6 months.
- **Secondary outcomes** will be differences in:
  1. OBP and ABPM reduction
  2. drug adherence (Morinsky)
  3. body weight changes
  4. number of unscheduled office visits
  5. number of prescribed antihypertensive drugs

# Study population

- Inclusion criteria




- ✓ Hypertensive patients with or without treatment and an office BP  $\geq 140/90$  mmHg at baseline visit
- ✓ ABPM  $\geq 130/80$  mmHg
- ✓ Age 18-75 years
- ✓ Possession of a smartphone compatible with the ESH CARE app and ability to use it.
- ✓ Possession of a validated BP measurement device.

- Exclusion criteria



- ❖ Office BP  $\geq 180/110$  mmHg
- ❖ eGFR  $< 45$  mL/min/1.73 m<sup>2</sup> (MDRD)
- ❖ Clinically overt cardiovascular disease (coronary artery disease, stroke, peripheral artery disease, heart failure)
- ❖ Secondary hypertension
- ❖ Atrial fibrillation
- ❖ Any significant systemic disease

# Study flow



## 6. ESH RESEARCH PROJECTS

- a. ESH BP CONTROL STUDY (*B. Jelakovic, K. Tsioufis*)
- b. ESH APP PILOT STUDY (*K. Tsioufis*)
- c. *ESH Emergency BP project (K. Tsioufis)*

**ESH registry of hypertensive  
URGencies and Emergencies  
(ESH-URGEM)**



## Objective

### Assessment of:

- The prevalence of hypertensive emergencies and urgencies
- The main causes of acute severe BP increase and the clinical characteristics of patients
- The management of these patients in the emergency department
- The medical instructions at discharge

## Methods

- ✓ The study will be conducted in the emergency department of each “ESH-Excellence Center” affiliated hospital during the everyday clinic work
- ✓ All cases presenting at the emergency department during 1 working day for at least 12 consecutive hours will be recorder
- ✓ Each center should record cases at least 1 day per week for a total period of 6 months.
- ✓ Enrollment will continue until all centers have completed the 6 months data collecting time frame

# Methods

## Study population

- **The inclusion and exclusion** criteria are the following:
- **Inclusion criteria:** -age  $\geq$  18 years
  - presentation at the emergency department with severe hypertension (grade 3)
- -Signed informed consent
- **Exclusion criteria:** dementia
  - terminal malignant and other systemic disease
  - inability of reporting previous medical history

# CASE REPORT FORM

Hospital-ESH center: .....

Country: .....

Physician's name: .....

Internal medicine  Cardiologist  Nephrologist  Neurologist  General practitioner

Patient's registry number: .....

Number of patients examined at the ED at the same date: .....

Date: ..... Time of presentation: .....

Name: ..... Age: ..... Phone number: ...../.....

Sex: Male  Female

Height: .....cm Weight: .....kg Smoking

1<sup>st</sup> BP at ED: ...../.....mmHg Heart rate: .....bpm ECG: HR..... SR  AF  PCM  LVH  LBBB  RBBB

2<sup>nd</sup> BP at ED: ...../.....mmHg

3<sup>rd</sup> BP at ED: ...../.....mmHg

**Causes reporting to the EDs:**

Random high BP measurement with symptoms:

Main symptoms: Acute dyspnea

Chest pain

Syncope

Neurological deficit

Visual disturbances

Headache-dizziness

Flushing

Vomiting

Palpitations

Epistaxis

Other: Rigor/Fever  Pain  Tremor  Other (determine).....

Random high BP measurement without symptoms:

Previous Antihypertensive treatment: YES  NO  if YES Duration of therapy: ..... years

Type of Antihypertensive medication: ACEs/ARBs  Calcium channel blockers  Centrally acting

B-blockers  Diuretics  Aldosterone antagonists

Nitrates  Other (define) .....

Single Pill Dual Antihypertensive Medication  Single Pill Triple Antihypertensive Medication

Other Medical history: CVD  HF  CKD  Stroke  AF  DM  PAD

Hyperlipidemia  Hypo/Hyperthyroidism  OSA  COPD

**Causes of acute BP increase:**

Acute Stress  Missing dose/s during the last day

Excessive salt intake  Missing dose/s during the last week

Excessive alcohol consumption  Missing dose/s during the last month/s

Excessive physical activity  Change of antihypertensive medication in the last week

Acute pain

BP rising Drugs: NSAIDs  Cortisone  Chemotherapy  Cocaine  Amphetamine  Other (define).....

Other (define).....

Serum exams: Hb: ..... Haemoglobin: ..... Platelet count: ..... Creat: ..... Urea: ..... Glu: ..... Na<sup>+</sup>: .....

K<sup>+</sup>: ..... LDH: ..... Troponin: ..... Haptoglobin: ..... CPK: ..... CPK-MB: .....

Admission: YES  NO

ESH registry of hypertensive  
URGencies and Emergencies  
(ESH-URGEM)



**European  
Society of  
Hypertension**

### NON ADMITTED PATIENTS

#### Management of BP at the ED:

per os       iv       sl       im

ACEs/ARBs       Nitrates       Nitrates       Diuretics

Calcium channel blockers       ~~B-blockers(except Labetalol)~~       Calcium channel blockers

Diuretics       Labetalol       ACEs

B-blockers       Diuretics

~~Anxiolytics~~       ~~Pheptolamine~~

Tts Nitrates       ~~Nitroprusside sodium~~

                         Nicardipine

                         Magnesium sulfate

                         Other (define).....

BP at 2 hours after presentation at the ED: ...../.....mmHg (optional).....      HR:.....bpm (optional)

1<sup>st</sup> BP before leaving the ED: ...../.....mmHg      HR:.....bpm

2<sup>nd</sup> BP before leaving the ED: ...../.....mmHg

3<sup>rd</sup> BP before leaving the ED: ...../.....mmHg

Time remaining in the ED before discharging: ..... mins

Antihypertensive treatment at discharge: same antihypertensive treatment: YES  NO

Additional treatment: ACEs/ARBs       Calcium channel blockers       Centrally acting

B-blockers       Diuretics       Aldosterone antagonists

Nitrates       Other (define).....

Single Pill Dual Antihypertensive Medication       Single Pill Triple Antihypertensive Medication

ESH registry of hypertensive  
URGencies and Emergencies  
(ESH-URGEM)

### ADMITTED PATIENTS

Diagnosis on admission: Acute pulmonary edema       Aortic syndrome       Hypertensive encephalopathy

Acute coronary syndrome       Acute kidney injury       Hypertensive retinopathy

Stroke: TIA       ~~ischemic~~       Hemorrhagic       Preeclampsia/Eclampsia/HELLP syndrome

Malignant hypertension       Other (define).....

#### Management of BP at the ED:

po       iv       sl       im

~~ACEs/ARBs~~       Nitrates       ~~Nitrates~~       ~~Diuretics~~

Calcium channel blockers       ~~B-blockers(except Labetalol)~~       Calcium channel blockers

Diuretics       Labetalol       ACEs

B-blockers       Diuretics

~~Anxiolytics~~       ~~Pheptolamine~~

Tts Nitrates       ~~Nitroprusside sodium~~

                         Nicardipine

                         Magnesium sulfate

                         Other (define).....

1<sup>st</sup> BP before leaving the ED and hospital admission: ...../.....mmHg      HR:.....bpm

2<sup>nd</sup> BP before leaving the ED and hospital admission: ...../.....mmHg

3<sup>rd</sup> BP before leaving the ED and hospital admission: ...../.....mmHg

Time remaining in the ED till hospital admission: ..... mins



European  
Society of  
Hypertension

# 7. YOUNG ESH MEMBERS AND ACTIVITIES

- a. ESH YOUNG INVESTIGATORS FORUM (*J. Polonia*)
- b. HYPERTENSION SUMMER SCHOOL 2019 (*K. Tsioufis*)

*Points for discussion*

# Young Investigator Forum – Council 3<sup>rd</sup> Nov 2018

- ❑ Letters were sent to all European Societies (Presidents)
- ❑ In Barcelona - Meeting with Presidents of Eur. HT. Societies invited to provide names of possible candidates to join YIF
- ❑ Prof Renata provided names, etc. of students of recent ESH Summer Schools
- ❑ Young doctors < 35yrs later < 40yrs
  - ❑ Name, gender, DOB, address, country and email
  - ❑ The scientific /and or work professional areas
    - ❑ - Basic research - description of research area;
    - ❑ - Activity linked to pharmaceutical industry
    - ❑ - Clinical practice in the cardiovascular field together with or without clinical research, thereby designating the area of their clinic interest.

# Young Investigator Forum – Council 3<sup>rd</sup> Nov 2018

## Objectives to YIF doctors

- ❑ To access a specific network of education and professional training sharing a broad spectrum of knowledge and experiences
- ❑ To have a facilitated access and a registration at low cost to the annual Congress of the ESH, besides the travel grants already available
- ❑ To participate in the Working Groups of the ESH and in their respective meetings
- ❑ To participate in specific sessions for Young Investigators during the annual Congress of the ESH



# Young Investigator Forum – Council 3<sup>rd</sup> Nov 2018

Answers received from National Hypertension Societies (number of candidates)

- Austria Hypertension Society (1)
- Belgian Hypertension Society (list will be sent)
- British and Irish Hypertension Society (list will be sent)
- French Hypertension Society (1)
- Hellenic Hypertension Society (43)
- Italian Society of Arterial Hypertension (18)
- Kazakh Society of Hypertension (3)
- Latvian Hypertension and Atherosclerosis Society (3)
- Sweden Hypertension Society (list will be sent)
- 25 Societies - no answer

# Young Investigator Forum – Council 3<sup>rd</sup> Nov 2018

## Positive Answers received from National Hypertension Societies (n=69)

Age	Number
26	3
27	6
28	5
29	6
30	1
31	5
32	5
33	10
34	6
35	6
36	3
37	3
38	1
39	2
Unnown	7
TOTAL	69

Female	38
Male	25
Unkown	6

Clinic	63
BP measurement & TOD	32
Diabetes Metabolic Syndrome	11
Epidemiology	6
Nephrology	7
Secondary HT	4
Therapeutics	3
Basic (Genetics)	1
Unkown	5

# Young Investigator Forum – Council 3<sup>rd</sup> Nov 2018

## □ Students in Summer Schools (2015-2016)

Country	Number
Argentina	4
Austria	2
Belarus	3
Belgium	3
Bulgaria	4
Croatia	4
Cyprus	2
Czech Repub	4
Denmark	3
Elvetia	1
Estonia	3
Finland	4
France	4
Germany	3
Greece	5
Hungary	2
Iraq	1
Ireland	3
Israel	4

Country	Number
Italy	3
Latvia	4
Lebanon	3
Lituania	2
Luxemburg	1
Moldova	1
Netherlands	4
Norway	4
Poland	4
Portugal	3
Romania	8
Russia	4
Serbia	3
Slovenia	3
Spain	2
Sweden	4
Ukrain	2
UK	4
TOTAL	118

Gender	n
Female	69
Male	49

Missing information:

- Ages
- Scientific fields of interest

## b. Hypertension Summer School 2019

- **1) Participants in summer school**
  - number
  - from which country
- **2) Interactive structure of program**
- **3) Local speakers**
- **4) Invited speakers**
- **5) Close cooperation between the person in charge of the summer school enquiries (Prof. Renata Cífková), the local organizer and the Council.**

**ESH Summer school 2019**  
**Dolce Attica Riviera Athens, 14-20 September 2019**



# 8. WORLD HYPERTENSION DAY, MAY 17, 2019

*(K. Tsioufis, C. Borghi, R. Kreutz, All)*

# ESH WORLD HYPERTENSION DAY CAMPAIGN

- The ESH **campaign** should focus on:
  - emphasizing the importance of hypertension as global health care concern and leading cause of cardiovascular mortality
  - raising awareness and disseminating the message of blood pressure testing
- **Leaflet:**

Short interview of all the presidents of National Hypertension Societies and brief statement on World Hypertension Day.
- Use of **social media** (e.g. creation of ESH World Hypertension Day hashtag)
- **Newspapers and magazines** listings of ESH campaign

## 8. WORLD HYPERTENSION DAY, MAY 17, 2019

- Open for Discussion



# 9. 2016 ESH GUIDELINES IN CHILDREN AND ADOLESCENTS: IMPLEMENTATION ACROSS EUROPE

*(E. Lurbe)*



**European  
Society of  
Hypertension**

## **Working Group on Blood Pressure in Children and Adolescents**


**Empar Lurbe, MD, PhD, FAHA  
Cardiovascular Risk Unit  
Hospital General Universitario  
University of Valencia, Spain**

# Working Group Activities 2018

- ✓ February 2018 – International Congress of Hypertension in Children and Adolescents, Valencia, Spain
- ✓ April 2018 – Publication of Editorial on the ESH/AAP Guidelines in Journal of Hypertension (published)
- ✓ April 2018 – Submission of the COST proposal to the European Commission (pending)
- ✓ Hypertension in children and adolescents (Springer Book) (completed)

# Planned Activities for the Future of the Working Group (I)

- ✓ Advance with the network for research in blood pressure values in children (COST)



# Planned Activities for the Future of the Working Group (II)

- ✓ 2016 ESH: Guidelines in children and adolescents: Improving the knowledge of its implementation across Europe.
  - ✓ General information
  - ✓ Blood pressure measurements
  - ✓ Out of office and central BP measurements
  - ✓ Final questions

# 2016 EUROPEAN SOCIETY OF HYPERTENSION GUIDELINES IN CHILDREN AND ADOLESCENTS: IMPROVING THE KNOWLEDGE OF ITS IMPLEMENTATION ACROSS EUROPE

## General Information

- Country

- Units in your country with expertise in managing Hypertension in pediatric age.

- The number of Excellence Centers devoted to Pediatric Hypertension.

- In the Annual Meeting of the Society are there sessions dedicated to HTN in pediatric age?

YES	NO
-----	----

- If YES, are sessions yearly scheduled?

YES	NO
-----	----

- Are pediatricians members of the National Society of Hypertension?

YES	NO
-----	----

# 2016 EUROPEAN SOCIETY OF HYPERTENSION GUIDELINES IN CHILDREN AND ADOLESCENTS: IMPROVING THE KNOWLEDGE OF ITS IMPLEMENTATION ACROSS EUROPE

## Blood pressure measurements

- Is screening performed systematically in children as a routine health care?

YES	NO
-----	----

- From what age is screening performed?

--

- How many measurements of BP are performed at a single visit and how is the BP value calculated for this visit?

Number of Measurements	
BP Calculation	

- Who performs the screening?

Pediatricians	Family doctors	Nurses
---------------	----------------	--------

# 2016 EUROPEAN SOCIETY OF HYPERTENSION GUIDELINES IN CHILDREN AND ADOLESCENTS: IMPROVING THE KNOWLEDGE OF ITS IMPLEMENTATION ACROSS EUROPE

- Once a diagnosis of HTN has been made, are children then referred to a reference unit?

YES	NO
-----	----

- What devices are used for measuring office BP?

--

- What Guidelines are followed?

ESH	
National Guidelines	
Other	

- In your country are data about prevalence of HTN

YES	NO
-----	----

- If yes, the prevalence of HTN is

HTN	<1%	<5%	6-10%	>10%
-----	-----	-----	-------	------



# 2016 EUROPEAN SOCIETY OF HYPERTENSION GUIDELINES IN CHILDREN AND ADOLESCENTS: IMPROVING THE KNOWLEDGE OF ITS IMPLEMENTATION ACROSS EUROPE

## *Out of office and central BP measurements*

- Is ABPM regularly used in pediatric hypertension?

YES	NO
-----	----

- Is home BP used for assessment of BP in children?

YES	NO
-----	----

- Is central BP regularly used in pediatric age?

YES	NO
-----	----

# 2016 EUROPEAN SOCIETY OF HYPERTENSION GUIDELINES IN CHILDREN AND ADOLESCENTS: IMPROVING THE KNOWLEDGE OF ITS IMPLEMENTATION ACROSS EUROPE

## Final questions

- Are physicians in your country interested in participating in the activities of the ESH working Group in Children and Adolescents?

YES	NO
-----	----

- If yes contact the Secretary of ESH Robyn Lynnch

- Additional comments and suggestions:

## 10. ESH ANNUAL MEETINGS

- a. ESH 2018 ANNUAL MEETING IN BARCELONA, FINAL REPORT  
(*A. Coca, M. Massaro, R. Kreutz*)
- b. ESH 2019 ANNUAL MEETING IN MILAN (*G. Mancia, M. Massaro*)
  - A. Persu proposal and colleague from India*
- c. ESH/ISH JOINT MEETING 2020 IN GLASGOW (*K. Tsioufis, M. Massaro*)
- d. ESH ANNUAL MEETINGS SOP (*R. Kreutz, M. Massaro*)
- e. ESH RULES AND ENDORSEMENTS OF THE PRE- AND POST- SATELLITE SYMPOSIA AND INDUSTRY SUPPORTED SYMPOSIA (*T. Kahan*)

## 10. ESH ANNUAL MEETINGS

a. ESH 2018 ANNUAL MEETING IN BARCELONA, FINAL REPORT (*A. Coca, M. Massaro, R. Kreutz*)



European  
Society of  
Hypertension

28<sup>th</sup>

EUROPEAN MEETING  
ON HYPERTENSION  
AND CARDIOVASCULAR  
PROTECTION

WWW.ESH2018.EU



JUNE 11 2018 FIRA  
BARCELONA  
HALL 8 - GRAN VIA BARCELONA


**ESH COUNCIL MEETING - 03/11/2018**



# ESH 2018 UPDATE



# PARTICIPANTS






# PARTICIPANTS



**PAID SPONSORED REGISTRATIONS 807**

**PAID INDIVIDUAL REGISTRATIONS 1380**

<b>TYPE of PARTICIPANT</b>	<b>#</b>
ESH MEMBER	210
NON MEMBER	1709
PARTICIPANT YOUNGER THAN 35	76
PARTICIPANT YOUNGER THAN 35 With 1 accepted abstract	192
FACULTY	282
PRESS	28
ACCOMMODATION GRANTS	49
FREE	57
EXHIBITORS/SPONSORS	45
<b>TOTAL</b>	<b>2648</b>








# PARTICIPANTS


	2016	2017	2018
<b>Participants (including FREE)</b>	<b>2291</b>	<b>2058</b>	<b>2070</b>
<b>Younger than 35</b>	<b>209</b>	<b>306</b>	<b>268</b>
<b>Faculty</b>	<b>250</b>	<b>224</b>	<b>282</b>
<b>Press</b>	<b>50</b>	<b>39</b>	<b>28</b>





# PARTICIPANTS

## TOP TEN COUNTRIES






## COUNTRIES WITH MORE THAN 20 DELEGATES

SPAIN	293	SLOVAK REPUBLIC	59
ITALY	231	UNITED KINGDOM	53
GREECE	138	ARGENTINA	52
POLAND	114	THE NETHERLANDS	49
RUSSIA	110	USA	46
FRANCE	95	HUNGARY	40
CZECH REPUBLIC	93	MEXICO	38
PORTUGAL	77	SOUTH KOREA	37
GERMANY	75	PHILIPPINES	31
TURKEY	69	BRAZIL	28
INDIA	66	CROATIA	28
JAPAN	66	UKRAINE	28
ROMANIA	65	LATVIA	25
CHINA	64	SWITZERLAND	24
BULGARIA	61	SERBIA	23
		SWEDEN	20



## FROM LATIN AMERICA AND SPAIN

SPAIN	295
ARGENTINA	53
MEXICO	39
BRAZIL	28
PARAGUAY	12
COLOMBIA	10
URUGUAY	10
PANAMA	8
DOMINICAN REP.	6
COSTA RICA	5
GUATEMALA	5
CHILE	3
EL SALVADOR	3
HONDURAS	2
NICARAGUA	2
VENEZUELA	2
CUBA	1
GUADELOUPE	1
<b>TOTAL</b>	<b>485</b>





**28<sup>th</sup>**

EUROPEAN MEETING  
ON HYPERTENSION  
AND CARDIOVASCULAR  
PROTECTION

 **European  
Society of  
Hypertension**  
WWW.ESH2018.EU



# SPONSORED SESSIONS

**1 SPONSORED LECTURE** (0 in 2017)

**MENARINI GROUP**

**2 SATELLITE SYMPOSIA** (2 in 2017)

**SERVIER**

**MERCK KGaA**

**1 HANDS-ON SESSION** (1 in 2017)

**SOMNOMEDICS**

**NO EDUCATIONAL SESSIONS** (1 in 2017)

**10 MINISYMPOSIA** (14 in 2017)

**CVRx**

**FERRER (n. 2)**

**MEDTRONIC**

**MENARINI GROUP (n. 2)**

**OMRON HEALTHCARE EUROPE**

**ReCOR MEDICAL**

**SERVIER (n. 2)**





# EXHIBITORS



**2017**

N. 28 EXHIBITORS

TOTAL SURFACE  
Approx 550 SQM

**2018**

N. 26 EXHIBITORS

TOTAL SURFACE  
Approx 470 SQM





# ABSTRACTS



RECEIVED AT FIRST DEADLINE	1021
LATE-BREAKERS RECEIVED	124

---

<b>TOTAL RECEIVED</b>	<b>1145</b>
-----------------------	-------------

---

ACCEPTED AT FIRST DEADLINE	1015
LATE-BREAKERS ACCEPTED	121

---

<b>TOTAL ACCEPTED</b>	<b>1136</b>
-----------------------	-------------

---

ORAL PRESENTATIONS	178
POSTERS	863
ORAL PRESENTATION IN POSTER AREA	71

NO-SHOW POSTERS	271
-----------------	-----

Abstracts not included in the Book due to lack of registration fee payment: 190

Abstracts withdrawn : 24



# ABSTRACTS



## RECEIVED BY COUNTRY

ITALY	121	ARGENTINA	16
RUSSIA	102	USA	29
SPAIN	70	BULGARIA	28
GREECE	69	SLOVAK REP.	26
CHINA	65	INDIA	23
JAPAN	52	AUSTRALIA	22
UKRAINE	50	SWITZERLAND	22
ROMANIA	42	BELGIUM	22
POLAND	42	CZECH REP.	21
FRANCE	42	KAZAKHSTAN	18
SOUTH KOREA	40	THE NETHERLANDS	15
PORTUGAL	38	MEXICO	15
GERMANY	38	TUNISIA	11
CROATIA	36	ALGERIA	10
UNITED KINGDOM	36	MALAYSIA	4
HUNGARY	20	NORWAY	8
SERBIA	19	TURKEY	8
BRAZIL	18	BELARUS	7





## RECEIVED BY COUNTRY

SINGAPORE	7
CAMEROON	6
CANADA	6
ISRAEL	6
SOUTH AFRICA	6
SWEDEN	6
MOROCCO	5
AUSTRIA	4
LITHUANIA	4
INDONESIA	3
TAIWAN	3
UZBEKISTAN	3
VENEZUELA	3
AZERBAIJAN	2
BOSNIA & HERZEGOVINA	2
CHILE	2

DENMARK	2
EGYPT	2
FINLAND	2
HONG KONG	2
IRAN	2
MOLDOVA	2
PAKISTAN	2
SLOVENIA	2
ALBANIA	1
GUADELOUPE	1
IRELAND	1
LATVIA	1
MAKEDONIJA	1
SAUDI ARABIA	1
THAILAND	1




## NO SHOW COUNTRIES


RUSSIA	26	GERMANY	3
CHINA	18	HUNGARY	3
UKRAINE	18	MALAYSIA	3
SPAIN	13	MOROCCO	3
ITALY	12	POLAND	3
SOUTH KOREA	12	VENEZUELA	3
JAPAN	11	AZERBAIJAN	2
ROMANIA	10	BELGIUM	2
INDIA	7	CAMEROON	2
FRANCE	6	CROATIA	2
GREECE	6	CZECH REPUBLIC	2
USA	6	INDONESIA	2
BULGARIA	5	IRAN	2
KAZAKHSTAN	5	SOUTH AFRICA	2
SERBIA	5	SWITZERLAND	2
BELARUS	4	TUNISIA	2
ALGERIA	3	TURKEY	2



## WITHDRAWN COUNTRIES

ARGENTINA	1
AUSTRALIA	1
CHINA	3
CROATIA	1
INDIA	2
ISRAEL	1
JAPAN	3
MALAYSIA	4
NORWAY	2
PAKISTAN	1
POLAND	1
SWEDEN	1
THE NETHERLANDS	1
UNITED KINGDOM	1
USA	1





## ABSTRACT BOOK

**ONLINE ABSTRACT BOOK - EDITOR WOLTERS KLUWER**

SUPPLEMENT OF THE JOURNAL OF HYPERTENSION

The congress abstract book is available on the journal of hypertension website  
and on the ESH congress website

**Cost for the online publication with 922 abstracts € 8.368,42**



**28<sup>th</sup>**

EUROPEAN MEETING  
ON HYPERTENSION  
AND CARDIOVASCULAR  
PROTECTION

**ESH** European  
Society of  
Hypertension  
WWW.ESH2018.EU



# SCIENTIFIC PROGRAMME

## SESSION TYPES

Breakfast Workshops	12
Joint Sessions	11
How-To Sessions	2
Meet-The-Experts	3
Topical Workshops	7
Teaching Seminars	3
Clinical Case Session	1
State of the Art Lectures	10
Lectures	7*

## SPECIAL SESSIONS

Balkan Symposium  
Brazilian Society of Cardiology  
Portuguese Session

## SPONSORED SESSIONS

Minisymposia	10
Satellite Symposia	2
Hands-on session	1
Lecture	1

## ORAL & POSTER SESSIONS

Oral Sessions	17
Poster Sessions	28
Oral Presentation Sessions	12
Late-breakers Oral sessions	3
Late-breakers Poster sessions	3

\* included in the programme by prof. Coca



# FACULTY



<b>ARGENTINA</b>	<b>10</b>	<b>GREECE</b>	<b>30</b>	PORTUGAL	7
AUSTRALIA	6	GUATEMALA	1	ROMANIA	2
AUSTRIA	2	HUNGARY	3	SERBIA	3
BELGIUM	5	INDIA	4	SLOVAK REPUBLIC	1
BOSNIA AND HERZEGOVINA	1	IRELAND	2	SLOVENIA	1
BRAZIL	7	ISRAEL	1	SOUTH AFRICA	2
CANADA	5	<b>ITALY</b>	<b>25</b>	SOUTH KOREA	6
CHINA	2	JAPAN	3	<b>SPAIN</b>	<b>48</b>
COLOMBIA	2	LATVIA	1	SWEDEN	5
CROATIA	3	LEBANON	1	SWITZERLAND	7
CUBA	1	LITHUANIA	1	THE NETHERLANDS	7
CZECH REPUBLIC	3	MEXICO	3	TUNISIA	1
DENMARK	1	MOZAMBIQUE	1	TURKEY	1
DOMINICAN REPUBLIC	1	NORWAY	1	<b>UNITED KINGDOM</b>	<b>15</b>
ESTONIA	2	PHILIPPINES	2	URUGUAY	1
FINLAND	2	POLAND	5	USA	6
FRANCE	6	PHILIPPINES	2	VENEZUELA	2
<b>GERMANY</b>	<b>15</b>	POLAND	5		


**TOTAL 282**



# BUDGET



<b>ANALYSIS</b>	<b>Milan 2017</b>	<b>Barcelona 2018</b>	
Industry Incomes: sponsorship, symposia, exhibition	€ 1.082.950,00	€ 823.375,00	- € 259.575,00
Registration Incomes	€ 1.062.553,00	€ 1.154.154,44	+ € 91.601,00
<b>Total Incomes</b>	<b>€ 2.145.503,00</b>	<b>€ 1.977.529,44</b>	<b>- € 167.973,56</b>





## FINAL BALANCE

Sponsorship incomes	€ 823.375,00
Registrations	€ 1.154.154,44
Expenditures	€ 1.616.871,06
Minimum Guaranteed ESH	€ 100.000,00
Minimum Guaranteed LOC	€ 100.000,00
<b>FINAL PROFIT (to be shared 50%)</b>	<b>€ 160.658,38</b>







AIM ITALY - AIM Group	
Written by: M.M.	
<b>28th European Meeting on Hypertension and Cardiovascular Protection</b>	
Date and Venue: Barcelona, June 8-11, 2018	
<b>FINAL BUDGET</b>	
<b>INCOMES</b>	<b>EURO</b>
SPONSORSHIPS	€ 59.550,00
EXHIBITION SPACES	€ 308.825,00
SATELLITE SYMPOSIA	€ 455.000,00
REGISTRATIONS	€ 1.154.154,44
<b>TOTAL INCOMES</b>	<b>€ 1.977.529,44</b>



**28<sup>th</sup>**

**EUROPEAN MEETING  
ON HYPERTENSION  
AND CARDIOVASCULAR  
PROTECTION**

**ESH** European  
Society of  
Hypertension  
WWW.ESH2018.EU



<b>GRAPHIC STUDY/PRINTED MATERIALS</b>	<b>€ 60.089,05</b>
<b>Abstract online (Journal of Hypertension)</b>	<b>€ 8.368,42</b>
<b>MARKETING AND COMMUNICATION ACTIVITIES PROMOTION OF THE CONGRESS EMAIL BLAST WEBSITE APP</b>	<b>€ 52.790,24</b>
<b>PRE-CONGRESS SECRETARIAT/GENERAL EXPENSES</b>	<b>€ 45.000,00</b>
<b>ONSITE SECRETARIAT: AIM COORDINATORS AND ONSITE STAFF, MANPOWER DURING THE CONGRESS</b>	<b>€ 86.307,00</b>
<b>INSURANCE</b>	<b>€ 12.000,00</b>
<b>CONGRESS VENUE /SIGNPOSTING AND DECORATION/ TECHNICAL EQUIPMENT</b>	<b>€ 411.862,63</b>
<b>TECHNICAL EQUIPMENT</b>	<b>€ 284.521,34</b>
<b>SIGNPOSTING/DECORATION MEETING ROOMS</b>	<b>€ 97.360,72</b>
<b>CONGRESS MATERIAL</b>	<b>€ 37.440,00</b>
<b>TRANSFERS</b>	<b>€ 2.336,59</b>



**28<sup>th</sup>**

**EUROPEAN MEETING  
ON HYPERTENSION  
AND CARDIOVASCULAR  
PROTECTION**

**ESH** European  
Society of  
Hypertension  
WWW.ESH2018.EU



<b>SPEAKERS</b>	<b>€ 67.696,90</b>
<b>FOOD &amp; BEVERAGE</b>	<b>€ 108.874,24</b>
<b>SOCIAL PROGRAMME</b>	<b>€ 79.046,00</b>
<b>MISCELLANEOUS</b>	<b>€ 65.425,00</b>
<b>AGENCY FEE 10% INCOMES</b>	<b>€ 197.752,94</b>
<b>TOTAL EXPENSES</b>	<b>€ 1.616.871,06</b>
<b>LOC MINIMUM GUARANTEE</b>	<b>€ 100.000,00</b>
<b>ESH MINIMUM GUARANTEE</b>	<b>€ 100.000,00</b>
<b>TOTAL</b>	<b>€ 1.816.871,06</b>
<b>FINAL PROFIT (to be shared 50%)</b>	<b>€ 160.658,38</b>



thank you

for your attention



# 10. ESH ANNUAL MEETINGS

## a. ESH 2018 ANNUAL MEETING IN BARCELONA, FINAL REPORT (A. Coca, M. Massaro, R. Kreutz)

### ESH 2018 Annual Meeting Report



THE 28<sup>TH</sup> EUROPEAN MEETING ON HYPERTENSION AND CARDIOVASCULAR PROTECTION, BARCELONA, SPAIN, JUNE 8–11, 2018

A GREAT SUCCESS!



Prof. J. Redon

From June 8 to 11, the 28<sup>th</sup> Annual Meeting on Hypertension and Cardiovascular Protection of the European Society of Hypertension (ESH) was held in Barcelona, Spain. More than 2,700 hypertension specialists from Europe and the rest of the world attended the 2018 congress and enjoyed the state of the art presentations of European and all over the world experts. The scientific program covered more than 100 sessions on recent topics in hypertension and associated diseases. Some of the sessions were organized as Joint Sessions with other Societies (Table 1).



Prof. K. Tsioufis

Special sessions were dedicated to practical aspects of hypertension management via Teaching, How-to, Meet the Expert and Clinical case sessions. During the opening session Prof. Josep Redon, Honorary President of the congress, Valencia (Spain), Prof. Antonio Coca, President of the Congress, Barcelona (Spain) and Prof. Konstantinos Tsioufis, President of ESH, Athens (Greece) welcomed the attendees to the meeting in Barcelona.



Prof. A. Coca

In addition, a brief but moving eulogy for Prof. Alberto Zanchetti was given by Prof. Giuseppe Mancía, Milan (Italy).

Prof. Zanchetti, a Past-President and honorary member of ESH, passed away at the age of 91 years in Milan on March 24<sup>th</sup> in 2018. Prof. Zanchetti was the driving force behind the ESH and its activities included the joint ESH/ESC Guidelines on Hypertension, which he first inspired in 2003. He was chief editor of the Journal of Hypertension since 1995. The most important highlight of the congress was the first presentation of essential recommendations of the 2018 ESC/ESH Joint Guidelines on the Management of Arterial Hypertension.



Prof. A. Zanchetti

More than 1700 individuals in the auditorium and more than 2000 via live streaming webcast attended the main session dedicated to this presentation.



Prof. G. Mancía, Prof. B. Williams

This session was a great success and was chaired by Prof. Bryan Williams, London (UK), and Prof. Giuseppe Mancía, as the two chairpersons and leading authors of the guidelines. The full text of the new joint guidelines (was) subsequently published in the European Heart Journal (1) and Journal of Hypertension (2), the two official journals of ESC and ESH, respectively.

One of the most important statements of the guidelines and eagerly awaited by the audience was related to the definition of hypertension. Prof. Krzysztof Narkiewicz, Dansk (Poland) confirmed in his presentation that hypertension is still defined as office systolic blood pressure (SBP) values  $\geq 140$  mmHg

doi:10.1093/eurheartj/ehy667

## ESH Annual Meeting 2018


### Reinhold Kreutz reports on the 28<sup>th</sup> European Meeting on Hypertension and Cardiovascular Protection that took place in Barcelona, Spain, 8–11 June



From 8–11 June, the 28<sup>th</sup> Annual Meeting on Hypertension and Cardiovascular Protection of the European Society of Hypertension (ESH) was held in Barcelona, Spain. More than 2700 hypertension specialists from Europe and the rest of the world attended the 2018 congress and enjoyed the state-of-the-art presentations of European and world-wide experts. The scientific programme covered more than 100 sessions on recent topics in hypertension and associated diseases. Some of the sessions were organized as Joint Sessions with other

Societies (Table 1). Special sessions were dedicated to practical aspects of hypertension management via Teaching, How-to, Meet the Expert and Clinical case sessions.

During the opening session Prof. Josep Redon, Honorary President of the Congress, Valencia (Spain), Prof. Antonio Coca, President of the Congress, Barcelona (Spain) and Prof. Konstantinos Tsioufis, President of ESH, Athens (Greece), welcomed the attendees to the meeting in Barcelona.



Opening session of the 2018 Annual ESH Meeting



# 10. ESH ANNUAL MEETINGS

b. ESH 2019 ANNUAL MEETING IN MILAN (*G. Mancia, M. Massaro*)

[www.esh2019.eu](http://www.esh2019.eu)

**29<sup>th</sup>** *European meeting*  
on **hypertension**  
and **cardiovascular**  
**protection**

**JUNE 21-24, 2019 - MILAN, ITALY**

**29<sup>th</sup>** european meeting  
on **hypertension**  
and **cardiovascular**  
**protection**

**JUNE 21-24, 2019 - MILAN, ITALY**

## *Preliminary Info*

<b>June 21, 22, 23, 24</b>	CONGRESS DAYS – SCIENTIFIC SESSIONS
<b>June 21 (Friday)</b>	CONGRESS OPENING
<b>June 22, 23, 24</b>	POSTER SESSIONS
<b>June 23 (Sunday)</b>	PRESIDENTIAL DINNER

[www.esh2019.eu](http://www.esh2019.eu)



**29<sup>th</sup>** *European meeting*  
on *hypertension*  
and *cardiovascular*  
*protection*

**JUNE 21-24, 2019 - MILAN, ITALY**

## Key Dates

Beginning of September	Letters to ESH Council Members and Presidents of National Societies for scientific proposals
October 5, 2018	Abstract submission open
December 20, 2018	Abstract submission close
Mid-January, 2019	Deadline for Referees
February 22 – March 22	Late Breaker Abstract Submission
March 2, 2019	ESH Programme Committee Meeting

**[www.esh2019.eu](http://www.esh2019.eu)**

**29<sup>th</sup>** european meeting  
on **hypertension**  
and **cardiovascular**  
**protection**

**JUNE 21-24, 2019 - MILAN, ITALY**

## **Preliminary Info**

Congress Venue  
MiCo Milano Congressi

Faculty Accommodation  
Hotel Enterprise

**[www.esh2019.eu](http://www.esh2019.eu)**

**29<sup>th</sup>** european meeting  
 on **hypertension**  
 and **cardiovascular**  
**protection**

**JUNE 21-24, 2019 - MILAN, ITALY**

**Provisional Timetable**

FRIDAY								
TIME 2017	TIME 2018	SILVER 1500 SEATS	BLUE HALL 450 SEATS	RED HALL 1 350 SEATS	RED HALL 2 350 SEATS	YELLOWHALL1 168 SEATS	YELLOWHALL2 144 SEATS	YELLOWHALL3 168 SEATS
13.30 14.30	13.30 14.30							
14.30 16.00	14.30 16.00		JOINT SESSION	JOINT SESSION	JOINT SESSION	ESH WORKING GROUP	PRACTICAL COURSE	PRACTICAL COURSE
16.00 17.30	16.00 17.30		ESH WORKING GROUP	ESH WORKING GROUP	ESH WORKING GROUP	ESH WORKING GROUP		
17.30 19.30	17.30 19.30	OPENING OF THE CONGRESS						

## SATURDAY

TIME 2017	TIME 2018	SILVER 1500 SEATS	BLUE HALL 450 SEATS	RED HALL 1 350 SEATS	RED HALL 2 350 SEATS	YELLOWHALL 1 168 SEATS	YELLOWHALL 2 144 SEATS	YELLOWHALL 3 168 SEATS	
07.45 08.45	07.45 08.45			BREAKFAST WORKSHOP	BREAKFAST WORKSHOP	BREAKFAST WORKSHOP	BREAKFAST WORKSHOP	08.00 - 09.00 meeting with president of national societies	
08.50 10.50	08.50 10.50			MINISYMPOSIUM	MINISYMPOSIUM	ORAL SESSION 1A	ORAL SESSION 1B	09.00 - 10.00 Meeting WG Coordinators	
10.55 12.25	11.00 12.30		TOPICAL WORKSHOP			ORAL SESSION 2A	ORAL SESSION 2B		
12.30 14.00	12.45 14.15	WORKING LUNCH (BOX LUNCH)							
12.30 14.00	12.45 14.15	TEACHING SEMINAR SESSION 1	SATELLITE SYMPOSIUM			ORAL SESSION 3A	LATE BREAKERS SESSION 1		
14.00 15.00	14.15 15.45		15.00-16.30 TOPICAL WORKSHOP ON HOT ISSUES	14.30-16.00 EDUCATIONAL SESSION	14.30 - 16.00 ORAL SESSION 3B	MEET-THE- EXPERT	MINISYMPOSIUM		
15.00 16.00	15.45 16.45					HOW-TO SESSION	CLINICAL CASE		
16.00 17.30	16.45 18.15	PLENARY SESSION							
17.30 19.00	18.15 19.45	ATTENDED POSTER SESSIONS AND BEST POSTERS DISCUSSION							18.00 - 18.30 ESH Excellence Centre

## SUNDAY

TIME 2017	TIME 2018	SILVER 1500 SEATS	BLUE HALL 450 SEATS	RED HALL 1 350 SEATS	RED HALL 2 350 SEATS	YELLOWHALL 1 168 SEATS	YELLOWHALL 2 144 SEATS	YELLOWHALL 3 168 SEATS	
07.45 08.45	07.45 08.45			BREAKFAST WORKSHOP	BREAKFAST WORKSHOP	BREAKFAST WORKSHOP	BREAKFAST WORKSHOP	08.00 - 09.00 meeting with president of national societies	
08.50 10.50	08.50 10.50		9.00-10.30 TOPICAL WORKSHOP	MINISYMPOSIUM	MINISYMPOSIUM	ORAL SESSION 4A	ORAL SESSION 4B	10.00 - 10.30 General Assembly	
10.55 12.25	11.00 12.30		11.00-12.00 MINISYMPOSIUM	11.00-12.00 MINISYMPOSIUM	TOPICAL WORKSHOP	ORAL SESSION 5A	LATE- BREAKERS SESSION 2	10.30 - 11.30 NEW ESH Members	
12.30 14.00	12.45 14.15	WORKING LUNCH (BOX LUNCH)							
12.30 14.00	12.45 14.15	TEACHING SEMINAR SESSION 2		SATELLITE SYMPOSIUM					
14.00 15.00	14.15 15.45					MEET-THE- EXPERT			
15.00 16.00	15.45 16.45		14.30-16.00 EDUCATIONAL SESSION	15.00-16.30 CLINICAL CASES (clinical- pathological conference)	15.00-16.30 TOPICAL WORKSHOP ON HOT ISSUES	HOW-TO SESSION	14.30-16.00 ORAL SESSION 6A		
16.00 17.30	16.45 18.15	PLENARY SESSION							
17.30 19.00	18.15 19.45	ATTENDED POSTER SESSIONS AND BEST POSTERS DISCUSSION							

## MONDAY

TIME 2017	TIME 2018	SILVER 1500 SEATS	BLUE HALL 450 SEATS	RED HALL 1 350 SEATS	RED HALL 2 350 SEATS	YELLOWHALL1 168 SEATS	YELLOWHALL2 144 SEATS	YELLOWHALL3 168 SEATS	
07.45 08.45	07.45 08.45			BREAKFAST WORKSHOP	BREAKFAST WORKSHOP	BREAKFAST WORKSHOP	BREAKFAST WORKSHOP	08.00 - 09.00 meeting with president of national societies	
08.50 10.50	08.50 10.50			9.00-10.30 TOPICAL WORKSHOP	ORAL SESSION 7A	ORAL SESSION 7B	LATE- BREAKERS SESSION 3		
10.55 12.25	11.00 12.30	PLENARY SESSION							
12.30 14.00	12.45 14.15	WORKING LUNCH (BOX LUNCH)							
12.30 14.00	12.45 14.15		TEACHING SEMINAR SESSION 3						
14.00 16.00	14.15 15.45	ATTENDED POSTER SESSIONS AND BEST POSTERS DISCUSSION							
14.00 16.00	14.15 15.45				14.30 - 15.30 HOW-TO SESSION	TOPICAL WORKSHOP ON HOT ISSUES	14.30 - 15.30 MEET-THE- EXPERT		

**29<sup>th</sup>** *European meeting*  
on *hypertension*  
and *cardiovascular*  
*protection*

**JUNE 21-24, 2019 - MILAN, ITALY**

## **Latest News**

### **ESH ABSTRACT BOOK**

published before the beginning of the Annual Meeting

### **PRACTICAL COURSES**

on Friday with a dedicated registration fee (€ 50,00)

### **NATIONAL SOCIETIES**

Confirmed also this year the free exhibition space.

### **STREAMING SESSIONS**

Provided to Asian and Latin American Sponsors

**29<sup>th</sup>** european meeting  
on **hypertension**  
and **cardiovascular**  
**protection**

**JUNE 21-24, 2019 - MILAN, ITALY**

## **Latest News**

### **ALBERTO ZANCHETTI AWARD:**


in 2019 the ALBERTO ZANCHETTI LIFE ACHIEVEMENT AWARD will be exceptionally replaced with a special award in Prof. Zanchetti's name, to assign to a young investigator, who will be officially awarded during the 2019 Annual Meeting.

The Award is promoted and supported by AIM Group International as a tangible way to remember and honour a person that has been a guide in the field, with the aim to improving and rewarding high impact researches.




# Floorplan 2017

## Level 0




# Floorplan 2017

## Level 1



# Floorplan 2017


## Level 2




-  SILVER
-  PREVIEW ROOM
-  VIP LOUNGE
-  WHITE HALLS 01, 02

# Floorplan 2019

Level 0



# Floorplan 2019



POSTER AREA: Maximum 10 rooms for a total of 369 posters per day  
+ 4 OPEN CORNERS for poster discussion.

**29<sup>th</sup>** *European meeting*  
on *hypertension*  
and *cardiovascular*  
*protection*

**JUNE 21-24, 2019 - MILAN, ITALY**

## Sponsors Update

### CONFIRMED

Servier  
Menarini Group  
SOMNOmedics GmbH  
Merck KGaA  
I.E.M.  
Wisepress

### NOT PARTICIPATING

Recordati  
Astrazeneca  
Bayer  
CVRx  
Miloftalmica  
Shenzen

### INTERESTED (PENDING)

Omron Healthcare Europe  
Medtronic  
A&D Company, Limited  
Novacor  
Microlife

**THANK YOU**

[www.esh2019.eu](http://www.esh2019.eu)

**29<sup>th</sup>** *European meeting*  
on ***hypertension***  
and ***cardiovascular***  
***protection***

**JUNE 21-24, 2019 - MILAN, ITALY**

## 10. ESH ANNUAL MEETINGS

c. ESH/ISH JOINT MEETING 2020 IN GLASGOW (*K. Tsioufis, M. Massaro*)

Representatives of ESH in Organizing Committee:

K. Tsioufis, R. Kreutz, G. Mancina







JOINT MEETING  
**ESH-ISH**  
2020  
Glasgow

May 29 - June 1, 2020  
**Scottish Exhibition Campus**  
Glasgow, United Kingdom  
[www.hypertension2020.org](http://www.hypertension2020.org)



**MEETING IN BEIJING**



# CONGRESS DATES

May 29

CONGRESS OPENING

May 30, 31  
June 1

CONGRESS DAYS  
SCIENTIFIC SESSIONS & POSTERS

May 31 (Sunday)

PRESIDENTIAL DINNER

# STATE OF THE ART

June 2018 →→ during ESH Barcelona - Congress Announcement: promotion with booth, gadget, flyers and ADV

September 2018 →→ during ISH Beijing - Promotion with booth, gadget, flyers. Sponsorship opportunities to be released to potential sponsors.

---

VENUE →→ Spaces and rates are fixed. Contract to be signed.

Preselected Hotels → Crowne Plaza\*; Radisson Red; Hilton Garden Inn; Village Hotel; Premier Inn\*\*; Campanile\*\*

\* *Faculty – 40 rooms*

\*\* *Accommodation Grants – 50 rooms*

# FUTURE DATES

From March 2019

Mailing and Social Media activities

June 2019

during ESH Milan - Promotion with booth, gadget, flyers. Sponsorship opportunities to be released to potential sponsors.

July 2019

Meeting with potential Sponsors in Glasgow at SEC

November 2019

Preparatory meeting with the ORGANIZING COMMITTEE

# KEY DATES TO BE DISCUSSED

September 2019	Letters to ESH-ISH Loc Members and Presidents of National and International Societies for scientific proposals
September 2019	Abstract Submission Open
End of October 2019	First Deadline for abstract submission
Mid-November 2019	Final Deadline for abstract submission
End of November	Deadline for Referees

# KEY DATES TO BE DISCUSSED

January 2020

**PROGRAMME COMMITTEE MEETING**  
(final selection of submitted Abstracts)  
**DATES TO BE DEFINED**

January 2020

Letter of Invitation to the Faculty Members

Mid-December 2020

Late-Breakers Abstract Submission Open

Mid-January 2020

Late-Breakers Abstract Submission Close

# CURRENT ORGANISING COMMITTEE

Prof. Dame Anna Dominiczak, *Chair ESH/ISH 2020*

Prof. Konstantinos Tsioufis, *ESH President*

Prof. Neil Poulter, *ISH President*

Prof. Murielle Bochud, *ESH Treasurer*

Prof. Franco Cappuccio, *BIHS President*

Prof. Christian Delles, *BIHS Treasurer - Treasurer ESH/ISH 2020*

Prof. Tony Heagerty, *ISH Lead for ESH/ISH 2020 Glasgow*

Prof. Reinhold Kreutz, *ESH Secretary*

Prof. Una Martin, *BIHS Vice-President*

Dr. Carmel McEniery, *BIHS Secretary*

Prof. Sandosh Padmanabhan, *Scientific Programme Lead ESH/ISH 2020*

Prof. Alta Schutte, *ISH President-Elect*

Prof. Maciej Tomaszewski, *ISH Secretary*

Prof. Rhian Touyz, *Deputy Chair ESH/ISH 2020*

## OTHER COMMITTEES?

- *SCIENTIFIC PROGRAMME COMMITTEE*
- *COMMITTEE FOR RELATIONS WITH PHARMA AND DEVICE COMPANIES*
- *LOCAL ORGANIZING COMMITTEE*



# SUGGESTED TOPICS

- I AGING
- 1 ATRIAL FIBRILLATION AND HEART FAILURE
- I BLOOD PRESSURE MEASUREMENT
- I BLOOD PRESSURE VARIABILITY
- I CARDIOVASCULAR RISK FACTORS
- 1 CEREBROVASCULAR DISEASES, STROKE, AND COGNITIVE DYSFUNCTION
- I CHILDREN AND ADOLESCENTS
- I CORONARY HEART DISEASE
- I DIABETES
- I ENDOCRINE HYPERTENSION
- 1 ENDOTHELIUM AND Atherosclerosis
- I EPIDEMIOLOGY OF HYPERTENSION AND METABOLIC DISORDERS
- 1 EXPERIMENTAL HYPERTENSION AND PHARMACOLOGY
- 1 GENETICS, GENOMICS, PHOTOMICS, METABOMICS
- I HEART AND HAEMODYNAMICS
- I HIGH ALTITUDE
- 1 INFLAMMATION AND IMMUNITY
- 1 INNOVATIVE TECHNIQUES AND DEVICES
- I KIDNEY
- I LARGE ARTERIES
- I LIFESTYLE CHANGES/LIPIDS/SAIT
- 1 MICROCIRCULATION/SMALL VESSELS
- 1 OBESITY AND METABOLIC SYNDROME
- 1 PREGNANCY
- 1 RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- 1 RESISTANT HYPERTENSION
- 1 SLEEP APNEA AND NEURAL MECHANISMS
- I SPORT AND EXERCISE
- 1 THERAPEUTICS AND CLINICAL TRIALS
- I TREATMENT ADHERENCE

# VENUE – SEC Centre


*Distance from the Airport – 15 minutes by car*  
*Distance from City Centre – 5 minutes by car*  
*Distance from selected hotels – 5 minutes walking*




# VENUE - SEC Centre



# VENUE - SEC Centre



# SEC Centre - Hall 4



# SEC Centre

## the World's first healthy venue


**Accredited as Silver Healthy Venue Level by the World Obesity Federation, the SEC is committed to:**

- Provide nutritious food options
- Promote active travel to and from the venue (free nextbikes available to all delegates)
- Design meetings and events to encourage less sedentary behaviour

# FACULTY ACCOMMODATION

## **Crowne Plaza Glasgow**

- Set on the banks of the River Clyde, with a direct internal link to the SEC Armadillo and Centre
- 283 modern and superbly furnished bedroom



# PRESIDENTIAL DINNER

## **Kelvingrove Art Gallery & Museum**

One of the city's most prominent landmarks and Glasgow's most magnificent venue for prestigious events.

It houses one of the finest civic art collections in Britain.

Guests can enjoy the atmosphere and rub shoulders with greats such as Botticelli, Rembrandt and van Gogh.





# GLASGOW CITY SUPPORT

- **Subvention funding** - 50% from Glasgow City Council  
50% from Visit Scotland
- **Social Programme** - Welcome Drink offered during  
Opening Reception
- **Marketing support** - City brand, Social media
- **Delegate welcome** - welcome signs  
city maps and guides  
discount for delegates in hotels and restaurants  
free museums and art galleries  
city bike hire  
discounted taxis from airport to city centre

## ESH/ISH Glasgow 2020 Committees

<b>President:</b>	A.F. Dominiczak (UK)
<b>Honorary Presidents:</b>	V. Dzau (USA) G. Mancia (Italy)
<b>Vice President:</b>	R. Touyz (UK)
<b>Secretary:</b>	S. Padmanabhan (UK)
<b>Treasurer:</b>	C. Delles (UK)
<b>Scientific Programme:</b>	S. Padmanabhan (UK) T. Guzik (UK)
<b>ESH President:</b>	K. Tsioufis (Greece)
<b>ISH President:</b>	A. Schutte (South Africa)
<b>BIHS President:</b>	F. Cappuccio (UK)

### Local Organising Committee

J. McMurray (UK)  
N. Sattar (UK)  
J. Petrie (UK)  
M. Brown (UK)  
A. Brady (UK)  
M. Caulfield (UK)  
M. Tomaszewski (UK)

<b>ESH</b>	K. Tsioufis (Greece) R. Kreutz (Germany) G. Mancia (Italy)
<b>ISH</b>	A. Schutte (South Africa) M. Schlaich (Australia) T. Unger (Netherlands)
<b>BIHS</b>	F. Cappuccio (UK) U. Martin (UK)

### Scientific Programme Committee

<b>Chairpersons:</b>	T. Guzik (UK) S. Padmanabhan (UK)
<b>Members:</b>	Executive Officers of ESH, ISH, BIHS

### Finance Committee:

<b>Chairperson:</b>	C. Delles (UK)
<b>Members:</b>	M. Bochud (Switzerland) T. Heagerty (UK) E. Agabiti Rosei (Italy) M. Schlaich (Australia) K. Tsioufis (Greece)

## European Society of Hypertension (ESH) Council

<b>President:</b>	K. Tsioufis (Greece)
<b>Vice-President:</b>	E. Lurbe (Spain)
<b>Secretary:</b>	R. Kreutz (Germany)
<b>Treasurer:</b>	M. Bochud (Switzerland)
<b>Officer-at-Large:</b>	B. Jelakovic (Croatia)
<b>Immediate Past President:</b>	E. Agabiti Rosei (Italy)

### Members

M. Azizi (France) ESH Hypertension Specialist Programme  
A. Januszewicz (Poland)  
T. Kahan (Sweden)  
J. Polonia (Portugal)  
P. van de Borne (Belgium) ESH Endorsement Programme  
B. Williams (UK)  
C. Borghi (Italy) Ex-officio ISH Representative  
D. Lovic (Serbia) Ex-officio Representative of the Presidents of ESH Affiliated Societies

### Executive Officers

G. Mancia (Italy) Chair, ESH Educational Committee, ESH Foundation  
G. Parati (Italy) Coordinator Working Group Activities  
D. Clement (Belgium) ESH Representative for contacts with the EU Officers  
A. Coca (Spain) Representative for Latin America Relations  
A. Manolis (Greece) Representative for Middle East Relations

## International Society of Hypertension (ISH) Council

### Executive Officers

<b>President:</b>	A. Schutte (South Africa)
<b>Vice President:</b>	F. Charchar (Australia)
<b>Secretary:</b>	T. Unger (Netherlands)
<b>Treasurer:</b>	M. Schlaich (Australia)
<b>Officer-at-Large:</b>	R. Wainford (USA)
<b>Immediate Past President:</b>	N. Poulter (UK)
<b>Chair, ISH Women in Hypertension Committee:</b>	M. Steckelings (Denmark)
<b>Chair, Communications Committee:</b>	D. Burger (Canada)
<b>Chair, Research, Science and Education Committee:</b>	C. Borghi (Italy)

### Members

R. Castillo (Philippines)  
M.C. Cho (South Korea)  
S. Ito (Japan)  
H. Itoh (Japan)  
N. Khan (Canada)  
Y. Kokubo (Japan)  
D. Prabhakaran (India)  
A. Ramirez (Argentina)  
G. Stergiou (Greece)  
M. Tomaszewski (UK)  
B. Williams (UK)

## Ex-Officio Members

Daniel Lackland (USA) WHL Representative  
Lewis Landsberg (USA) Board of Management of the Journal of Hypertension  
Lars H. Lindholm (Sweden) Hypertension News  
Trefor Morgan (Australia) APSH Representative  
Enrico Agabiti-Rosei (Italy) ESH Representative

## British & Irish Hypertension Society (BIHS)

### Executive Committee

<b>President:</b>	F. Cappuccio
<b>Vice-President:</b>	U. Martin
<b>Secretary:</b>	C. McEniery
<b>Treasurer:</b>	C. Delles

### Members

M. Glover  
C. Clark  
C. Rajkumar  
A. Greenstein

### Young Investigator Network Representative

J. Sheppard

# ESH ANNUAL

## MEETINGS

operating procedures

(R. Kreutz, M. Massaro)

	time	FRIDAY June 21	SATURDAY June 22	SUNDAY June 23	MONDAY June 24
morning	08:00	<b>ESH COUNCIL MEETING in the Hotel</b>	Meeting with president of national societies (2)	Meeting with president of national societies (2)	Meeting with president of national societies (2)
	08:30				
	09:00		Meeting (3)		
	09:30		WG Coordinators		
	10:00			<b>General Assembly (5)</b>	
	10:30			NEW ESH Members (6)	immediate transition encouraged
	11:00				
	11:30				<b>CLOSING CEREMONY (8) (define podium)</b>
	12:00				
	12:30				
	13:00				
	13:30				
afternoon	14:00				
	14:30				
	15:00				
	15:30				
	16:00			clear room 15 minutes before	
	16:30	clear room 15 minutes before		<b>AWARDS PLENARY SESSION (7)</b>	
	17:00	<b>OPENING CEREMONY + WELCOME COCKTAIL (1)</b>			
	17:30				
	18:00		ESH Excellence Centre (4)		
	18:30				
	19:00				

	ESH members chairing this session / activity
1.	On podium: ESH President, Annual Meeting President/Honorary President, ESH secretary
2.	ESH President, Vice-President, Secretary and available Council Members
3.	WG Coordinator of Council, ESH President, Vice-President, Secretary
4.	ESH Excellence Centre Coordinator, President, Vice-President, Secretary
5.	On podium: ESH President, Immediate Past President (Moderator), Vice-President, Treasurer, ESH secretary
6.	ESH Vice President and Secretary
7.	On podium all members of Award Committee: ESH President, Secretary, and at least 3 additional Council Members assigned each year (e.g. Annual Congress President and others)
8.	On podium: ESH President, Annual Meeting President/Honorary President, Meeting President of the next Annual Meeting

## 10. ESH ANNUAL MEETINGS

e. ESH RULES AND ENDORSEMENTS OF THE PRE- AND POST- SATELLITE SYMPOSIA AND INDUSTRY SUPPORTED SYMPOSIA (*T. Kahan*)

# Rules for the endorsement of pre/post ESH satellite symposia and industry supported symposia

A Coca, T Kahan (co-chairs); C Borghi, G Mancina, A Manolis, G Parati

## Issues to clarify

- The same rules apply for pharma, medical technology, and laboratory industry.
- The sponsor is free to suggest topic.
- The sponsor is free to suggest speakers/chairs. Gender and geographic diversity should be considered.
- There should be a settled written agreement between speaker/chair and sponsor before the activity.
- The sponsor should be offered to view the proposed presentation 2 weeks before the actual presentation.
- The sponsor may comment on the context within 1 week.
- Ownership of the contents/intellectual property of a presentation Speaker/sponsor?
- The copyright of the presentation must be clarified in the written agreement.

*Awaiting* comments from AMGEN.

*Pending* contact Italian (Farmindustria) and Spanish (consider also other) for the prevalent rules and the practice for industry sponsored symposia.

Draft documents to be circulated to the board by the end of the year

# 11. CURRENT STATUS ON RELATIONSHIPS WITH OTHER SCIENTIFIC SOCIETIES

## a. ESC/ESH GUIDELINES (G. Mancia)

### a. TRANSLATION OF GUIDELINES

a. Full text

b. Pocket Guidelines

# 11. CURRENT STATUS ON RELATIONSHIPS WITH OTHER SCIENTIFIC SOCIETIES

## b. JOINT SESSIONS ESH/ESC AT ESH AND ESC 2019 MEETINGS (K. Tsioufis)

Controversies in the Management of hypertension

Chairpersons: **C. Tsioufis**, TBA (by ESC)

European vs American Guidelines on Hypertension in children and adolescents: The impact on the prevalence of white-coat and masked hypertension

**Professor Lurbe Empar**

Primary Aldo. Diagnostic Approach

**Professor Azizi Michel**

## 12. ESH POSITION PAPERS

- a. NUTRACEUTICAL (C. Borghi)
- b. Management of Supine Hypertension in Patients with Neurogenic Orthostatic Hypotension: Jordan et al.



# 12. ESH POSITION PAPERS

## a. NUTRACEUTICAL (C. Borghi)

### Nutraceutical and Blood Pressure control.

Authors:

Affiliations:

Corresponding Authors

#### Index

(Length of the paper to be discussed with the Editor J Hypertension. Present version 14152 words, expected final < 14500-two paragraph are still lacking but some others must be reduced)

1. Introduction. C.Borghi, Tsioufis C

2. Epidemiology of elevated blood pressure: summary of evidence. G.Mancia, Milan

3. High-normal blood pressure, risk of CVD and therapeutic approach G.Grassi, Milan

4. Diet and blood pressure control: summary of evidence and limitations D.Clement, Brussels

5. Nutraceuticals: definition, properties, classification and trial design. C.Borghi, Bologna

6. Foods: (<350 words each, 3-4 ref's)

- Non-roasted green coffee\*
- Pomegranate juice\*
- Tea\*
- Karkadè\*
- Beetroot Juice\*
- Sesame\*

7. Nutrients: Bochud M, Desideri GB, Jelakovic B, Polonia J (< 350 words each,3-4 ref's)

- Omega-3 Polyunsaturated fatty acids (PUFAs)\*
- Proteins, peptides and amino-acids (L-arginine) **EAR**
- Calcium\*
- Magnesium\*
- Potassium\*
- Vitamins (B6, C, D)\*
- Prebiotics and Soluble fibers\*

8. Non nutrient nutraceuticals: Kreutz R, Van de Borne P, Coca A, Burnier M (< 350 words each,3-4 ref's)

- Resveratrol and grape seed extracts\*
- Cocoa flavonoids\*
- Soy Isoflavones\*
- Aged garlic extract\*
- Lycopene\*
- Pycnogenol\*
- Alpha Lipoic acid
- Co-enzyme Q10\*
- Slow-release melatonin\*
- Taurine\*
- Hawthorn\*
- Probiotics\*
- 

9. ESH position and suggestions in clinical practice (1000 words, no ref's) C.Borghi, Tsioufis C (Missed)

13. ESH NEWSLETTERS FOR 2019  
(P. Van de Borne)

# Suggestions for novel Newsletters

- WG on Blood Pressure in Children and Adolescents  
Chairman Prof. Empar Lurbe [empar.lurbe@uv.es](mailto:empar.lurbe@uv.es)
- WG on Obesity Diabetes and the High Risk Patient  
Chairman Prof. Vasilios Kotsis [vkotsis@auth.gr](mailto:vkotsis@auth.gr)
- Working group on VASCULAR STRUCTURE AND  
FUNCTION Chairman Prof. Pierre Boutouyrie France  
[pierre.boutouyrie@egp.aphp.fr](mailto:pierre.boutouyrie@egp.aphp.fr)
- WG on Hypertension and Cardiovascular Risk  
Assessment in Subjects Living in or Emigrating from Low  
Resource Settings Chairman Prof. Pietro Amedeo  
Modesti [pamodesti@unifi.it](mailto:pamodesti@unifi.it)

# 14. ESH ENDORSEMENT (P. Van de Borne)

# ENDORSEMENT / NWSL

Dear Prof. Borghi,

It is with great pleasure I confirm on behalf European Society of Hypertension, endorsement by the Society of the International Symposium “*Uric Acid and Cardiometabolic Disease: From Bench to Bedside*”, November 13<sup>th</sup>-14<sup>th</sup>, **2018** in Bologna (Italy).

Dear Prof. Zebekakis,

It is with great pleasure I confirm on behalf European Society of Hypertension, endorsement by the Society of the 3<sup>rd</sup> Hypertension School to be held in Athens, November 29<sup>th</sup>-December 2<sup>nd</sup>, 2018.

Dear Prof. Doumas,

It is with great pleasure I confirm on behalf European Society of Hypertension, endorsement by the Society of the 19<sup>th</sup> National Congress on Arterial Hypertension to be held in Thessaloniki, April 18<sup>th</sup>-19<sup>th</sup>, 2019.

**REF: Payment for ESH endorsement of the conference “Menarini Asia Pacific 4th CardioConnect Conference”, on March 9th, 2019, in Ho Chi Minh City, Vietnam.**

Congratulations for the organization of the Conference on March 9<sup>th</sup> 2019 in Ho Chi Minh City, Vietnam.

Dear Prof. Marius Miglinas,

It is my pleasure to inform you on behalf of the ESH that the 1<sup>th</sup> North - Eastern Postgraduate Course on “Arterial Stiffness and Vascular Aging” that will take place on the 15<sup>th</sup> and 16<sup>th</sup> of November 2018 in Vilnius, Lithuania,


Dear Prof. Zoltán Járαι,

It is my pleasure to inform you on behalf of the ESH that the first joint ESH-HSH session organized on the 21st of September during the 26th Annual Congress of the Hungarian Society of Hypertension on ‘Hypertension and Cardiovascular Protection’ from the 20th to the 22nd of September, 2018, in Siófok, Hungary, fulfills the strict criteria set out by the ESH, and therefore

Prof. Dr. Detlev Ganten  
President World Health Summit  
WHS Foundation GmbH  
c/o Charité – Universitätsmedizin Berlin  
Charitéplatz 1  
10117 Berlin, Germany

Leading Opinion

## Implementing the Proclamation of Stroke and Potentially Preventable Dementias

Vladimir Hachinski<sup>1</sup> , Detlev Ganten<sup>2</sup>, Daniel Lackland<sup>3</sup>, Reinhold Kreutz<sup>4</sup>, Konstantinos Tsioufis<sup>5</sup> and Werner Hacke<sup>6</sup>; on behalf of the World Stroke Organization, the World Heart Federation, the World Hypertension League and the European Society of Hypertension

International Journal of Stroke  
2018, Vol. 13(8) 780-786  
© 2018 World Stroke Organization  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/1747493018799965  
journals.sagepub.com/home/wso



### RE: IMPLEMENTING THE PROCLAMATION OF STROKE AND POTENTIALLY TREATABLE DEMENTIAS

Dear Prof. Ganten,

It is our great pleasure to support your initiative on stroke and dementia in the context of the upcoming 2018 World Health Summit Meeting in Berlin. We are very enthusiastic about your corresponding paper, since this topic is of major interest of our Society in our fight against stroke, dementia and other cardiovascular and renal diseases associated with high blood pressure.

Please find attached also our logo you may wish to use in any promotional activities in relation to this topic.

De : StruijkerBoudier, H (PHAR-TOX) <h.struijkerboudier@maastrichtuniversity.nl>  
À : Van de Borne Philippe  
Cc : Moyra Barbier  
Objet : ESH book endorsement

Date : lun. 15/10/2018 1

Message Table of Contents PVS book.docx (17 Ko)

Dear Philippe,

As a follow up to our recent telephone call I herewith send you a request for an endorsement by the ESH for a book we intend to publish in the first half of 2019.

This book is intended as a tribute to the many contributions of the Paris Vascular School (PVS) to cardiovascular research, in particular in relation to hypertension. In addition it is intended to give a contemporary overview of major vascular basic and clinical research issues, again with a particular focus on hypertension.


<b>Chapter 3.</b> <i>M O'Rourke, J Topouchian, N Westerhof</i>	<b>Wave reflections: Fingerprints on the Arterial Pulse (3000 words + approx. 25 refs)</b>
<b>Chapter 4.</b> <i>R Asmar, C Vlachopoulos</i>	<b>Evolution of basic hemodynamic principles (3000 words + approx. 25 refs)</b>
<b>Chapter 5.</b> <i>S Léhoux, D Henrion</i>	<b>Mechanical factors determining vascular tone (3000 words + approx. 25 refs)</b>
<b>Chapter 6.</b> <i>P Lacolley, V Regnault, J Humphrey</i>	<b>Molecular basis of vascular mechanotransduction (3000 words + approx. 25 refs)</b>
<b>Chapter 7.</b> <i>J-S Silvestre, P Maddedu</i>	<b>Vascular development, angiogenesis (3000 words + approx. 25 refs)</b>
<b>Chapter 8.</b> <i>P Boutouyrie, P Segers, A Hoeks</i>	<b>Evolution of techniques to assess vascular structure and function (3000 words + approx. 25 refs)</b>
<b>Chapter 9.</b> <i>A Bénétos, H Smulyan</i>	<b>Vascular changes during ageing (3000 words + approx. 25 refs)</b>
<b>Chapter 10.</b> <i>J Blacher, A Yannoutsos, J-J Mourad, Y Zhang</i>	<b>Clinical impact of vascular measurements (3000 words + approx. 25 refs)</b>
<b>Chapter 11.</b> <i>A Protogerou, G Mitchell, A Avolio</i>	<b>Pulse pressure amplification, target organ damage and cardiovascular mortality (3000 words + approx. 25 refs)</b>
<b>Chapter 12.</b> <i>G London, B Pannier, S Aoun-Bahous</i>	<b>Vascular changes in renal disease (3000 words + approx. 25 refs)</b>
<b>Chapter 13.</b> <i>Z Mallat, C Binder</i>	<b>Vascular changes in atherosclerosis (3000 words + approx. 25 refs)</b>
<b>Chapter 14.</b> <i>J-B Michel, B Mees</i>	<b>Aortic aneurysms (3000 words + approx. 25 refs)</b>
<b>Chapter 15.</b> <i>S Laurent, L Van Bortel</i>	<b>Future therapeutic options (3000 words + approx. 25 refs)</b>



B. DE BECKER, C. BORGHI, M. BURNIER, P. VAN DE BORNE

Uric Acid and Hypertension: An Update. Year: 2018 Issue: 19 Newsletter No.: 69

<http://www.eshonline.org/esh-content/uploads/2018/06/Uric-Acid-and-Hypertension-An-Update.pdf>



B. DE BECKER, C. BORGHI, M. BURNIER, P. VAN DE BORNE  
ESH Expert Opinion: Uric acid and Hypertension  
Journal of Hypertension 2018

Prof. Empar Lurbe,  
Prof. Vasilios Kotsis,  
Prof. Pierre Boutouyrie,  
Prof. Pietro Amedeo Modesti

Have been asked to coordinate the writing of a NWLS on behalf of the Working Groups

on Blood Pressure in Children and Adolescents

on Obesity Diabetes and the High Risk Patient

on VASCULAR STRUCTURE AND FUNCTION

on Hypertension and Cardiovascular Risk Assessment in Subjects Living in or Emigrating from  
Low Resource Settings

# ENDORSEMENT / NWSL

Dear Prof. Borghi,

It is with great pleasure I confirm on behalf European Society of Hypertension, endorsement by the Society of the International Symposium “*Uric Acid and Cardiometabolic Disease: From Bench to Bedside*”, November 13<sup>th</sup>-14<sup>th</sup>, 2018 in Bologna (Italy).

Dear Prof. Zebekakis,

It is with great pleasure I confirm on behalf European Society of Hypertension, endorsement by the Society of the 3<sup>rd</sup> Hypertension School to be held in Athens, November 29<sup>th</sup>-December 2<sup>nd</sup>, 2018.

Dear Prof. Doumas,

It is with great pleasure I confirm on behalf European Society of Hypertension, endorsement by the Society of the 19<sup>th</sup> National Congress on Arterial Hypertension to be held in Thessaloniki, April 18<sup>th</sup>-19<sup>th</sup>, 2019.

# 15. Report by the Editor Journal of Hypertension (G. Mancia)

## 16. ANY OTHER ISSUES (All)

Relation with EU (D. Clement)

## 16. ANY OTHER ISSUES (All)

Relation with EU (D. Clement)

Antihypertensive drugs and Cancer:  
new ESH Working Group on Drug Safety - Adherence  
(Cardiovascular / Cardiometabolic Drug Therapy) (R. Kreutz)

*Any other ...*

*Photo (s) from ESH Council (Members)*

## 16. ANY OTHER ISSUES (All)

- Cancer

## 15. DATES FOR FUTURE COUNCIL MEETING

*(R. Kreutz)*

- a. MILAN – Saturday MARCH 2, 2019
- b. MILAN - Friday JUNE 21, 2019
- c. Fall Meeting 2019, date and location suggestions

# 16. CLOSURE OF THE MEETING

*(K. Tsioufis)*